<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429713</article-id><article-id pub-id-type="pmcid-ver">PMC12429713.1</article-id><article-id pub-id-type="pmcaid">12429713</article-id><article-id pub-id-type="pmcaiid">12429713</article-id><article-id pub-id-type="doi">10.3390/ijms26178660</article-id><article-id pub-id-type="publisher-id">ijms-26-08660</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effects of Exposure of PHMG-p, a Humidifier Disinfectant Component, on Eye Dryness: A Study on a Rat Model Based on <sup>1</sup>H-NMR Metabolomics</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0714-8596</contrib-id><name name-style="western"><surname>Lee</surname><given-names initials="JD">Jung Dae</given-names></name><xref rid="af1-ijms-26-08660" ref-type="aff">1</xref><xref rid="af2-ijms-26-08660" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3203-462X</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="HY">Hyang Yeon</given-names></name><xref rid="af1-ijms-26-08660" ref-type="aff">1</xref><xref rid="af2-ijms-26-08660" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oh</surname><given-names initials="SB">Soo Bean</given-names></name><xref rid="af3-ijms-26-08660" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3846-4260</contrib-id><name name-style="western"><surname>Goo</surname><given-names initials="H">Hyeyoon</given-names></name><xref rid="af3-ijms-26-08660" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cho</surname><given-names initials="KJ">Kyong Jin</given-names></name><xref rid="af3-ijms-26-08660" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1357-1633</contrib-id><name name-style="western"><surname>Hwang</surname><given-names initials="GW">Gi-Wook</given-names></name><xref rid="af4-ijms-26-08660" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="S">Suhkmann</given-names></name><xref rid="af5-ijms-26-08660" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2139-2296</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="KB">Kyu-Bong</given-names></name><xref rid="af1-ijms-26-08660" ref-type="aff">1</xref><xref rid="af2-ijms-26-08660" ref-type="aff">2</xref><xref rid="c1-ijms-26-08660" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Yang</surname><given-names initials="SF">Shun-Fa</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-26-08660"><label>1</label>College of Pharmacy, Dankook University, Cheonan 31116, Republic of Korea; <email>ljd0734@nate.com</email> (J.D.L.); <email>festivalkim@gmail.com</email> (H.Y.K.)</aff><aff id="af2-ijms-26-08660"><label>2</label>Center for Human Risk Assessment, Dankook University, Cheonan 31116, Republic of Korea</aff><aff id="af3-ijms-26-08660"><label>3</label>College of Medicine, Dankook University, Cheonan 31116, Republic of Korea; <email>ohsu9212@naver.com</email> (S.B.O.); <email>ghy1204@hanmail.net</email> (H.G.); <email>perfectcure@dankook.ac.kr</email> (K.J.C.)</aff><aff id="af4-ijms-26-08660"><label>4</label>Division of Environmental and Health Sciences, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai 981-8558, Japan; <email>hwang@tohoku-mpu.ac.jp</email></aff><aff id="af5-ijms-26-08660"><label>5</label>Department of Chemistry, Center for Proteome Biophysics, and Chemistry Institute for Functional Materials, Pusan National University, Busan 46241, Republic of Korea; <email>suhkmann@pusan.ac.kr</email></aff><author-notes><corresp id="c1-ijms-26-08660"><label>*</label>Correspondence: <email>kyubong@dankook.ac.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>26</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496188</issue-id><elocation-id>8660</elocation-id><history><date date-type="received"><day>02</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-26-08660.pdf"/><abstract><p>Polyhexamethylene guanidine phosphate (PHMG-p), a widely used disinfectant component in household humidifiers, has been implicated in various health issues, including pulmonary toxicity. Many people use humidifiers to improve dry eye disease (DED). The current study was performed to elucidate the effect of PHMG-p on eye dryness in a rat model using metabolomics. Male Sprague Dawley rats were exposed to PHMG-p (0.1% and 0.3%) following a previously established DED induction model using scopolamine hydrobromide and desiccation stress. Ocular surface damage was assessed using corneal fluorescein staining, tear volume measurement, and tear break-up time (TBUT). Plasma and urine samples were analyzed using <sup>1</sup>H-NMR-based metabolomics to identify metabolic alterations associated with PHMG-P-p exposure and DED pathogenesis. PHMG-p exposure exacerbated DED symptoms, as evidenced by a significant reduction in tear volume, shorter TBUT, and increased corneal damage compared to the control group. Metabolomic profiling identified distinct metabolic changes in PHMG-p-exposed groups, including alterations in glutamate, glycine, citrate, and succinate metabolism. These metabolic changes correlated with increased levels of inflammatory cytokines such as IL-1&#946;, IL-6, and TNF-&#945; in the corneal and lacrimal gland tissues. Our findings suggest that PHMG-p exposure contributes to DED pathophysiology by inducing metabolic disturbances and inflammatory responses in the ocular surface. This study highlights the need for further investigation into the potential risks of PHMG-p exposure on ocular health and provides novel insights into the metabolic underpinnings of DED.</p></abstract><kwd-group><kwd>PHMG-p</kwd><kwd>eye dryness</kwd><kwd>NMR</kwd><kwd>metabolomics</kwd><kwd>biomarker</kwd></kwd-group><funding-group><award-group><funding-source>National Research Foundation of Republic of Korea (NRF)</funding-source><award-id>NRF-2017R1A2B4004758</award-id><award-id>NRF-2020R1I1A1A01072862</award-id><award-id>RS-2024-00463346</award-id></award-group><funding-statement>This work was supported by a National Research Foundation of Republic of Korea (NRF) grant (NRF-2017R1A2B4004758, NRF-2020R1I1A1A01072862 and RS-2024-00463346) funded by the Republic of Korea government (MEST).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-26-08660"><title>1. Introduction</title><p>Dry eye disease (DED), also known as dry eye syndrome or keratoconjunctivitis sicca, is a multifactorial and chronic ocular condition characterized by a loss of tear film homeostasis [<xref rid="B1-ijms-26-08660" ref-type="bibr">1</xref>]. It affects the ocular surface and is associated with symptoms such as burning, itching, heaviness, eye fatigue, dryness, facial flushing, and blurred vision. DED occurs when the eyes fail to maintain an adequate tear layer, essential for lubricating and nourishing the ocular surface. This leads to increased osmotic pressure in the tear film, resulting in irritation and inflammation, further exacerbated by the release of pro-inflammatory mediators [<xref rid="B2-ijms-26-08660" ref-type="bibr">2</xref>]. With an estimated prevalence of 5&#8211;50% globally, DED is one of the most common ophthalmic disorders [<xref rid="B3-ijms-26-08660" ref-type="bibr">3</xref>]. DED has a variety of causes and risk factors. Age is a significant contributor, with older individuals being more susceptible. Certain medications, such as antihistamines, antihypertensives, and antidepressants, have been associated with DED development. Autoimmune diseases like Sj&#246;gren&#8217;s syndrome, environmental factors such as low humidity and high airflow, and meibomian gland dysfunction, which affects the lipid layer of the tear film, are also prominent causes [<xref rid="B1-ijms-26-08660" ref-type="bibr">1</xref>]. Symptoms include stinging or burning sensations, pressure, a gritty feeling, redness, blurry vision, excessive tearing, and difficulty wearing contact lenses, all of which significantly affect the quality of life [<xref rid="B1-ijms-26-08660" ref-type="bibr">1</xref>,<xref rid="B4-ijms-26-08660" ref-type="bibr">4</xref>].</p><p>DED is typically diagnosed using methods such as ocular surface staining, non-invasive evaluation of tear break-up time (TBUT), and measurement of osmotic pressure [<xref rid="B5-ijms-26-08660" ref-type="bibr">5</xref>]. The pathophysiology of DED involves inflammation of the ocular surface and increased osmotic pressure of the tear film, which play critical roles in disease progression [<xref rid="B6-ijms-26-08660" ref-type="bibr">6</xref>,<xref rid="B7-ijms-26-08660" ref-type="bibr">7</xref>]. Common features include inflammation of the ocular surface and major tear glands. Key inflammatory markers such as human leukocyte antigen-DR (HLA-DR) and interleukin (IL)-1&#946; have been detected in the conjunctiva, contributing to the apoptosis or cytotoxicity of conjunctival epithelial cells [<xref rid="B8-ijms-26-08660" ref-type="bibr">8</xref>,<xref rid="B9-ijms-26-08660" ref-type="bibr">9</xref>,<xref rid="B10-ijms-26-08660" ref-type="bibr">10</xref>,<xref rid="B11-ijms-26-08660" ref-type="bibr">11</xref>]. Increased tear osmotic pressure has also been linked to the overexpression of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-&#945;), IL-1, and IL-6, perpetuating the inflammatory cascade in DED [<xref rid="B12-ijms-26-08660" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-08660" ref-type="bibr">13</xref>,<xref rid="B14-ijms-26-08660" ref-type="bibr">14</xref>].</p><p>TNF-&#945;, IL-1&#946;, and IL-6 are central to DED pathogenesis. These cytokines are significantly elevated in the tear film and ocular tissues of DED patients, correlating with disease severity and maintaining the chronic inflammatory state [<xref rid="B15-ijms-26-08660" ref-type="bibr">15</xref>,<xref rid="B16-ijms-26-08660" ref-type="bibr">16</xref>]. TNF-&#945; and IL-6 interact synergistically, amplifying the inflammatory response and stimulating antigen-presenting cell maturation and T-cell function, which further sustain the inflammatory cycle. Elevated IL-1&#946; levels inhibit neurotransmitter secretion, reducing tear production and exacerbating ocular surface damage [<xref rid="B16-ijms-26-08660" ref-type="bibr">16</xref>]. Furthermore, TNF-&#945; is pivotal in orchestrating inflammation, with topical TNF-&#945; blockers shown to suppress inflammation in the cornea and lacrimal glands by reducing IFN-&#947;, IL-21, and IL-6 expression [<xref rid="B15-ijms-26-08660" ref-type="bibr">15</xref>,<xref rid="B17-ijms-26-08660" ref-type="bibr">17</xref>].</p><p>The therapeutic importance of targeting these cytokines is evident in the effectiveness of anti-inflammatory treatments. For instance, cyclosporine A combined with artificial tears significantly reduces TNF-&#945;, IL-1&#946;, and IL-6 levels, improving clinical outcomes in DED patients [<xref rid="B15-ijms-26-08660" ref-type="bibr">15</xref>,<xref rid="B16-ijms-26-08660" ref-type="bibr">16</xref>]. These findings highlight the critical role of pro-inflammatory cytokines in the pathogenesis and progression of DED and underscore the potential of targeted therapies in managing this disease.</p><p>According to recent data, the number of patients visiting hospitals for DED in the Republic of Korea ranges between 2.3 million and 2.5 million annually. As of 2022, women accounted for 66.5% of the total patients, approximately twice the number of men. By age group, patients in their 60s represented the largest proportion at 19.4%, followed by those in their 50s (19.1%) and 40s (15.1%). These statistics highlight that DED is a highly prevalent condition in the Republic of Korea, particularly among women and middle-aged to elderly individuals [<xref rid="B18-ijms-26-08660" ref-type="bibr">18</xref>].</p><p>Polyhexamethylene guanidine phosphate (PHMG-p) is a guanidine derivative widely used as a biocidal disinfectant due to its fungicidal and bactericidal properties against Gram-positive and Gram-negative bacteria. In the Republic of Korea, PHMG-p was commonly utilized as a disinfectant in household humidifiers to prevent microbial contamination [<xref rid="B19-ijms-26-08660" ref-type="bibr">19</xref>,<xref rid="B20-ijms-26-08660" ref-type="bibr">20</xref>]. However, in the Republic of Korea, the use of PHMG-p in household humidifiers led to a public health crisis, prompting investigations into its toxicity and long-term effects [<xref rid="B21-ijms-26-08660" ref-type="bibr">21</xref>]. PHMG-p exposure was found to primarily target the respiratory system, causing severe health risks, which has driven extensive research across various fields. Studies on the toxicity of PHMG-p have been conducted in areas such as respiratory health, cytotoxicity, immunology, hematology, histology, and omics [<xref rid="B22-ijms-26-08660" ref-type="bibr">22</xref>,<xref rid="B23-ijms-26-08660" ref-type="bibr">23</xref>,<xref rid="B24-ijms-26-08660" ref-type="bibr">24</xref>,<xref rid="B25-ijms-26-08660" ref-type="bibr">25</xref>,<xref rid="B26-ijms-26-08660" ref-type="bibr">26</xref>,<xref rid="B27-ijms-26-08660" ref-type="bibr">27</xref>,<xref rid="B28-ijms-26-08660" ref-type="bibr">28</xref>]. Due to its harmful effects, ongoing research continues to elucidate the mechanisms of PHMG-p-induced damage and explore potential therapeutic strategies for affected individuals.</p><p>The hypothesis that the increase in DED prevalence might be associated with the use of humidifier disinfectants was supported by several observations: (1) the use of humidifiers was often recommended for the treatment of DED [<xref rid="B29-ijms-26-08660" ref-type="bibr">29</xref>], (2) while the prevalence of DED has been steadily increasing before and after the discontinuation of humidifier disinfectants in 2011, there was an unexpected decline in 2013, and (3) women, who were more likely to engage in indoor activities, exhibited a prevalence rate more than twice that of men, who were more exposed to outdoor activities [<xref rid="B30-ijms-26-08660" ref-type="bibr">30</xref>]. This is contrary to the expected trend if factors such as yellow dust or fine particulate matter were the primary causes of DED. Therefore, investigating the correlation between humidifier disinfectants and DED is both meaningful and important.</p><p>Metabolomics has emerged as a powerful tool in disease diagnosis and treatment, offering valuable insights into pathophysiological mechanisms and potential therapeutic targets [<xref rid="B31-ijms-26-08660" ref-type="bibr">31</xref>,<xref rid="B32-ijms-26-08660" ref-type="bibr">32</xref>]. By comprehensively characterizing metabolites within biological systems, metabolomics provides a unique perspective on disease processes and treatment outcomes, enabling a deeper understanding of the molecular basis of various conditions [<xref rid="B33-ijms-26-08660" ref-type="bibr">33</xref>,<xref rid="B34-ijms-26-08660" ref-type="bibr">34</xref>,<xref rid="B35-ijms-26-08660" ref-type="bibr">35</xref>]. In the field of disease diagnosis, metabolomics has demonstrated significant potential across a broad spectrum of applications. One of its most promising contributions is the identification of biomarkers for early detection of diseases such as cancer, diabetes, and cardiovascular disorders, allowing for timely intervention and improved patient outcomes [<xref rid="B34-ijms-26-08660" ref-type="bibr">34</xref>,<xref rid="B36-ijms-26-08660" ref-type="bibr">36</xref>,<xref rid="B37-ijms-26-08660" ref-type="bibr">37</xref>]. Clinically, metabolomics has already been implemented in newborn screening programs, enabling the detection of over 50 inherited metabolic disorders, thereby facilitating early treatment and prevention of severe complications [<xref rid="B38-ijms-26-08660" ref-type="bibr">38</xref>,<xref rid="B39-ijms-26-08660" ref-type="bibr">39</xref>]. Moreover, its potential in infectious disease diagnosis is gaining recognition, as it may allow for the direct detection of pathogens or the identification of host-response biomarkers specific to particular infections [<xref rid="B33-ijms-26-08660" ref-type="bibr">33</xref>,<xref rid="B40-ijms-26-08660" ref-type="bibr">40</xref>,<xref rid="B41-ijms-26-08660" ref-type="bibr">41</xref>]. In the context of complex diseases, metabolomics has provided novel insights into the metabolic underpinnings of conditions such as diabetes, Alzheimer&#8217;s disease, atherosclerosis, and cancer, uncovering biomarkers and metabolic pathways previously unrecognized [<xref rid="B42-ijms-26-08660" ref-type="bibr">42</xref>,<xref rid="B43-ijms-26-08660" ref-type="bibr">43</xref>,<xref rid="B44-ijms-26-08660" ref-type="bibr">44</xref>,<xref rid="B45-ijms-26-08660" ref-type="bibr">45</xref>].</p><p>Moreover, many studies have employed metabolomics to identify biomarkers and understand the disease mechanisms of DED. Tear metabolomics has been a focal point of research due to the direct relevance of tear composition to ocular surface health. A cross-sectional study involving 113 participants (85 with DED and 28 controls) analyzed reflex tears using UPLC-Q/TOF-MS/MS, revealing 48 metabolites associated with DED incidence [<xref rid="B42-ijms-26-08660" ref-type="bibr">42</xref>]. These metabolites showed variations across age groups and were primarily involved in glucose metabolism, amino acid metabolism, and glutathione metabolism. Furthermore, metabolic changes were correlated with clinical indicators such as the Ocular Surface Disease Index (OSDI) and fluorescein breakup time [<xref rid="B42-ijms-26-08660" ref-type="bibr">42</xref>]. Serum metabolomics has also provided valuable insights, as evidenced by a large-scale study involving 2819 subjects from the Twins UK cohort [<xref rid="B43-ijms-26-08660" ref-type="bibr">43</xref>]. This study identified 222 serum metabolites and highlighted the critical role of androgen metabolism in DED development, particularly among females [<xref rid="B43-ijms-26-08660" ref-type="bibr">43</xref>]. Additionally, combined tear and saliva metabolomics studies have advanced the understanding of evaporative DED, particularly in female patients. Recent research identified 56 metabolites in tears that significantly differed between DED patients and controls, with these metabolites linked to meibum composition, antioxidative properties, and the ocular microbiome [<xref rid="B44-ijms-26-08660" ref-type="bibr">44</xref>]. Saliva analysis revealed lower levels of hypotaurine in patients with tear film instability, suggesting a potential link between systemic metabolism and ocular health [<xref rid="B44-ijms-26-08660" ref-type="bibr">44</xref>]. Animal model studies have further contributed to the field, with scopolamine-induced DED models used to analyze plasma and urine metabolites [<xref rid="B45-ijms-26-08660" ref-type="bibr">45</xref>,<xref rid="B46-ijms-26-08660" ref-type="bibr">46</xref>]. These studies aimed to identify potential biomarkers and elucidate metabolic changes associated with DED [<xref rid="B45-ijms-26-08660" ref-type="bibr">45</xref>,<xref rid="B46-ijms-26-08660" ref-type="bibr">46</xref>]. In therapeutic research, in situ metabolomics using MALDI-MSI has identified potential treatment targets [<xref rid="B47-ijms-26-08660" ref-type="bibr">47</xref>]. A study published in Nature (2025) demonstrated increased glutamine levels in the cornea following combined mesenchymal stem cell and thymosin beta-4 therapy. This research identified glutaminase 1 (GLS1) as a potential therapeutic target for DED, paving the way for novel treatment approaches [<xref rid="B47-ijms-26-08660" ref-type="bibr">47</xref>].</p><p>Therefore, in previous studies, we identified biomarkers of dry eye disease (DED) using <sup>1</sup>H-NMR in a rat model [<xref rid="B45-ijms-26-08660" ref-type="bibr">45</xref>]. Building on this foundation, we aimed to investigate the correlation between PHMG-p, a component of humidifier disinfectants, and its role in inducing or exacerbating DED.</p></sec><sec sec-type="results" id="sec2-ijms-26-08660"><title>2. Results</title><sec id="sec2dot1-ijms-26-08660"><title>2.1. Corneal Fluorescein Staining and Corneal Damage</title><p>On day 13, corneal epithelial damage was assessed using corneal fluorescein staining. Both eyes of each rat in the groups (<italic toggle="yes">n</italic> = 6) were examined, and representative corneal fluorescein staining images from each group on day 13 after DED induction are shown in <xref rid="ijms-26-08660-f001" ref-type="fig">Figure 1</xref>A. The corneal damage scores were 0.68 &#177; 0.49 and 1.75 &#177; 0.75 in the control group and the DED group, respectively. The scores for the PC group, DED + PHMG-p 0.1% group, and DED + PHMG-p 0.3% group were 2.25 &#177; 0.75, 2.08 &#177; 0.29, and 2.08 &#177; 0.34, respectively. Additionally, the PHMG-p 0.1% group and the PHMG-p 0.3% group showed scores of 2.25 &#177; 0.75 and 1.42 &#177; 0.34, respectively. The corneal damage scores were significantly higher in all groups compared to the control group (<xref rid="ijms-26-08660-f001" ref-type="fig">Figure 1</xref>B).</p></sec><sec id="sec2dot2-ijms-26-08660"><title>2.2. Tear Volume</title><p>The mean tear volumes across the experimental groups are summarized as follows. In the control group, the tear volume was 0.24 &#177; 0.08 &#956;L. In the DED group, the tear volume was reduced to 0.13 &#177; 0.05 &#956;L, confirming a significant decrease in tear production and the successful induction of DED compared to the control group. In the PC group (DED + BAC), treated with benzalkonium chloride (0.1%) after DED induction, the tear volume was further reduced to 0.11 &#177; 0.04 &#956;L, showing an exacerbation of DED symptoms. The groups treated with 0.1% or 0.3% PHMG-p after DED induction exhibited mean tear volumes of 0.12 &#177; 0.07 &#956;L and 0.15 &#177; 0.02 &#956;L, respectively, while the groups treated with PHMG-p (0.1% or 0.3%) alone had mean tear volumes of 0.07 &#177; 0.03 &#956;L and 0.30 &#177; 0.10 &#956;L, respectively. All groups, except for the group treated with 0.3% PHMG-p alone, showed significant differences compared to the control group (<xref rid="ijms-26-08660-f001" ref-type="fig">Figure 1</xref>C).</p></sec><sec id="sec2dot3-ijms-26-08660"><title>2.3. Tear Break-Up Time (TBUT)</title><p>The TBUT results of the control group and the DED group were 7.63 &#177; 2.64 s and 5.08 &#177; 1.92 s, respectively, after 13 days of exposure to desiccation stress. The PC group showed a TBUT of 3.79 &#177; 0.70 s. The groups treated with 0.1% or 0.3% PHMG-p after DED induction had TBUT values of 3.81 &#177; 1.37 s and 5.40 &#177; 1.12 s, respectively, while the groups treated with PHMG-p alone had TBUT values of 5.57 &#177; 0.69 s and 6.32 &#177; 0.50 s, respectively. Compared to the control group, TBUT was significantly reduced in all groups except for the group treated with only PHMG-p 0.3% (<xref rid="ijms-26-08660-f001" ref-type="fig">Figure 1</xref>D). TBUT was calculated using the mean of three measurements.</p></sec><sec id="sec2dot4-ijms-26-08660"><title>2.4. Conjunctival Goblet Cell Counts</title><p>The total number of goblet cells in the control group was 89 &#177; 8.66 cells/mm<sup>2</sup>, while in the DED group, the goblet cell count was significantly reduced to 17 &#177; 13.75 cells/mm<sup>2</sup>. The PC group exhibited a further reduction in goblet cell count, with 3 &#177; 5.20 cells/mm<sup>2</sup>. In the DED + PHMG-p 0.1% and DED + PHMG-p 0.3% groups, the goblet cell counts were 0.33 &#177; 0.58 cells/mm<sup>2</sup> and 38 &#177; 4.37 cells/mm<sup>2</sup>, respectively. The PHMG-p 0.1% group showed a goblet cell count of 3 &#177; 3.61 cells/mm<sup>2</sup>, while the PHMG-p 0.3% group demonstrated 75.5 &#177; 7.00 cells/mm<sup>2</sup>. Compared to the control group, the goblet cell count was significantly reduced in all groups except for the group treated with only PHMG-p 0.3%. Representative histological findings of goblet cell counts in each group are presented in <xref rid="ijms-26-08660-f002" ref-type="fig">Figure 2</xref>.</p></sec><sec id="sec2dot5-ijms-26-08660"><title>2.5. Inflammatory Cytokine Concentrations in the Cornea</title><p>The expression levels of IL-6, IL-1&#946;, and TNF-&#945; in the corneal tissue were assessed and are shown in <xref rid="ijms-26-08660-f003" ref-type="fig">Figure 3</xref>A. The DED group exhibited a significant increase in all three pro-inflammatory cytokines compared to the control group. The PC group also showed elevated cytokine levels, although the increase was less pronounced compared to the DED group for some markers. In the groups treated with PHMG-p after DED induction, IL-6 and TNF-&#945; levels were significantly elevated in the DED + PHMG-p 0.3% group compared to the control group. IL-1&#946; levels were similarly increased in the DED + PHMG-p 0.3% group, while the DED + PHMG-p 0.1% group exhibited moderately elevated cytokine levels. In the PHMG-p-only groups, IL-6, IL-1&#946;, and TNF-&#945; were slightly increased in the PHMG-p 0.1% group but remained lower than those observed in the DED + PHMG-p groups. The PHMG-p 0.3% only group showed relatively lower cytokine expression levels compared to DED + PHMG-p 0.3%. Representative histological images of IL-1&#946;, IL-6, and TNF-&#945; staining are presented in <xref rid="ijms-26-08660-f003" ref-type="fig">Figure 3</xref>B. Immunohistochemical staining revealed positive immunoreactivity for IL-6, IL-1&#946;, and TNF-&#945; in the DED and DED + PHMG-p groups (indicated by red arrows). These groups exhibited dense chromogenic deposition, suggesting enhanced inflammatory signaling in the corneal tissue. In contrast, weaker or minimal staining was observed in the control and PHMG-p-only groups, indicating relatively low basal cytokine expression. The staining intensity and distribution correspond well with the quantified data shown in <xref rid="ijms-26-08660-f003" ref-type="fig">Figure 3</xref>A, highlighting the pro-inflammatory effects of DED and PHMG-p exposure at the tissue level.</p></sec><sec id="sec2dot6-ijms-26-08660"><title>2.6. Plasma NMR Profile</title><p>NMR spectra for plasma samples of control or treated groups were obtained. The spectral region of &#948;0.0&#8211;10 was segmented into regions of 0.04 ppm width, providing 250 integrated regions in each NMR spectrum for plasma samples. Visual examination of NMR spectra displayed different intensities of several metabolites between groups. The spectral binning data were obtained through NMR analysis of S&#8211;D rat plasma samples.</p><p>The global profiling data exhibited clear clustering among the control, DED, PC, and PHMG-p-treated groups on the principal component analysis (PCA). Additionally, the orthogonal projections to latent structures discriminant analysis (OPLS-DA) data showed a clear separation of clusters between the groups, as analyzed using the SIMCA-P multivariate analysis program (<xref rid="ijms-26-08660-f004" ref-type="fig">Figure 4</xref>A,B). A total of 41 endogenous metabolites were identified using Chenomx NMR Suite ver. 8.3 (Chenomx Inc., Edmonton, AB, Canada) in plasma samples of control, DED, PC group and PHMG-p-treated groups. The score plots of PCA and OPLS-DA in plasma target profiling demonstrated clearly discriminable clustering between groups. The VIP showed sorting of endogenous metabolites in the order of contribution to the separation of clustering (<xref rid="ijms-26-08660-f005" ref-type="fig">Figure 5</xref>). Significant metabolites were selected according to a VIP value of more than 0.5, which determined meaningfully important metabolites (<xref rid="ijms-26-08660-f005" ref-type="fig">Figure 5</xref>C). In addition, we compared the results with the DED-related metabolites identified in our previous study [<xref rid="B44-ijms-26-08660" ref-type="bibr">44</xref>]. In a previous study, the major metabolites associated with DED were identified as 1,3-dimethylurate, 2-hydroxyisobutyrate, alanine, citrate, creatine, glucose, glutamate, lactate, N-nitrosodimethylamine, and succinate. A total of 20 major plasma metabolites were selected in the present study, including 2-hydroxyisobutyrate, 3-hydroxybutyrate, acetate, alanine, arginine, citrate, creatine, glucose, glutamate, glutamine, glycerol, glycine, isoleucine, lactate, leucine, pyruvate, serine, succinate, threonine, and valine. Among them, eight metabolites&#8212;2-hydroxyisobutyrate, alanine, citrate, creatine, glucose, glutamate, lactate, and succinate&#8212;were identified, which were the same as those reported in the previous study [<xref rid="B45-ijms-26-08660" ref-type="bibr">45</xref>]. <xref rid="ijms-26-08660-f006" ref-type="fig">Figure 6</xref> shows the changes in metabolites for each group.</p><p>After performing pathway analysis for the selected metabolites using the MetaboAnalyst 6.0 program (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.metaboanalyst.ca">http://www.metaboanalyst.ca</uri> (accessed on 11 November 2024)) [<xref rid="B48-ijms-26-08660" ref-type="bibr">48</xref>], 21 metabolic pathways were predicted in plasma samples. Among these pathways, glycine and serine metabolism, glutamate metabolism, arginine and proline metabolism, glutathione metabolism, the citric acid cycle, amino sugar metabolism, and fatty acid biosynthesis were identified (<xref rid="ijms-26-08660-t001" ref-type="table">Table 1</xref>). <xref rid="ijms-26-08660-f007" ref-type="fig">Figure 7</xref> illustrates the expected changes in plasma metabolic pathways in the PHMG-p-treated group after DED induction.</p></sec><sec id="sec2dot7-ijms-26-08660"><title>2.7. Urinary NMR Profile</title><p>NMR spectra for urine samples of control or treated groups were obtained. The spectral region of &#948;0.0&#8211;10 was segmented into regions of 0.04 ppm width, providing 250 integrated regions in each NMR spectrum for urine samples. Visual examination of NMR spectra displayed different intensities of several metabolites between groups.</p><p>The global profiling data showed clear separation of clustering among the control, DED, PC, and PHMG-p-treated groups on the par-scale of PCA and OPLS-DA models (<xref rid="ijms-26-08660-f004" ref-type="fig">Figure 4</xref>C,D). A total of 88 endogenous metabolites were identified using Chenomx NMR Suite ver. 8.3 (Chenomx Inc., Edmonton, AL, Canada) in the urine samples of each group. PCA and OPLS-DA score plots in urinary target profiling exhibited clear discrimination of clustering between groups (<xref rid="ijms-26-08660-f008" ref-type="fig">Figure 8</xref>). VIP demonstrated sorting of endogenous metabolites in the order of contribution to separation of clustering. Significant metabolites were selected according to a VIP value of more than 0.5, which determined meaningfully important metabolites (<xref rid="ijms-26-08660-f008" ref-type="fig">Figure 8</xref>C).</p><p>In a previous study, 26 urinary metabolites were screened in the DED group, among which phenylalanine, phenylacetate, pantothenate, glycine, succinate, methanol, valine, propylene glycol, histidine, threonine, lactate, and acetate showed significant differences [<xref rid="B45-ijms-26-08660" ref-type="bibr">45</xref>]. In this study, a total of 36 major urinary metabolites were identified, including 1-methylnicotinamide, 2-oxoglutarate, 3-hydroxybutyrate, 4-hydroxyphenylacetate, 4-pyridoxate, acetate, acetone, allantoin, asparagine, cis-aconitate, citrate, dimethylamine, ethanol, ethylene glycol, formate, glucose, glutamine, glycine, hippurate, lactate, lysine, N6-acetyllysine, N-acetylglycine, N-methylhydantoin, N-phenylacetylglycine, ornithine, phenylalanine, propylene glycol, sarcosine, succinate, succinylacetone, taurine, trigonelline, trimethylamine, trimethylamine N-oxide, and uracil. Among them, 12 metabolites were identical to those reported in previous studies: acetate, cis-aconitate, glycine, lactate, N6-acetyllysine, N-methylhydantoin, phenylalanine, propylene glycol, sarcosine, succinate, taurine, and trimethylamine. <xref rid="ijms-26-08660-f009" ref-type="fig">Figure 9</xref> shows the changes in metabolites for each group.</p><p>Pathway analysis for the selected metabolites in urine samples was also performed in the same manner as for plasma samples, and 26 metabolic pathways were predicted. The predicted metabolic pathways include the citric acid cycle, glutamate metabolism, aspartate metabolism, arginine and proline metabolism, glycine and serine metabolism, amino sugar metabolism, fatty acid biosynthesis, and taurine and hypotaurine metabolism (<xref rid="ijms-26-08660-t002" ref-type="table">Table 2</xref>). The expected changes in urinary metabolic pathways in the PHMG-p-treated group after DED induction are illustrated in <xref rid="ijms-26-08660-f010" ref-type="fig">Figure 10</xref>.</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-26-08660"><title>3. Discussion</title><p>In our previous study, we induced DED in rats and used a metabolomics approach to develop biomarkers and elucidate the mechanisms underlying DED [<xref rid="B45-ijms-26-08660" ref-type="bibr">45</xref>,<xref rid="B46-ijms-26-08660" ref-type="bibr">46</xref>]. The present study investigated the effects of polyhexamethylene guanidine phosphate (PHMG-p), a humidifier disinfectant component, on DED using a rat model and metabolomic analysis.</p><p>Several studies have investigated the ocular effects of polyhexamethylene guanidine (PHMG), highlighting its potential toxicity and concentration-dependent impact on eye health. A study by Lee et al. (2021) examined the role of fibrosis as a manifestation of PHMG toxicity in the eye using Statens Seruminstitut Rabbit Cornea (SIRC) cells [<xref rid="B49-ijms-26-08660" ref-type="bibr">49</xref>]. The study demonstrated that PHMG exposure led to an increased expression of fibrosis-related biomarkers, including TGF-&#946;, &#945;-SMA, MMPs, and TIMPs, at both the gene and protein levels. Furthermore, oxidative stress levels were significantly elevated in PHMG-treated cells, supporting the hypothesis that PHMG can induce fibrosis in the cornea. Another study by Park et al. (2019) evaluated the eye irritation potential of PHMG using a reconstructed human cornea-like epithelium model (EpiOcular&#8482;) [<xref rid="B50-ijms-26-08660" ref-type="bibr">50</xref>]. The results indicated that raw PHMG materials, with an active ingredient concentration of 26%, were classified under UN GHS Category 1 (serious eye damage) or Category 2 (eye irritation). However, when PHMG solutions were diluted to 0.13% or lower, no significant eye irritation was observed at the tested concentrations. A more recent systematic review by Ivanov et al. (2024) provided a comprehensive assessment of PHMG&#8217;s toxicity and safety through various exposure routes, including ocular contact [<xref rid="B51-ijms-26-08660" ref-type="bibr">51</xref>]. The review concluded that PHMG-p solutions below 0.13% appear to be safe for the human corneal epithelium. However, despite this, even low concentrations of PHMG have been associated with corneal fibrosis, as demonstrated in animal studies. These findings suggest that while diluted PHMG solutions may not cause immediate eye irritation, chronic exposure could still pose a long-term risk to corneal health, particularly through fibrotic changes and oxidative stress-related damage. Although several studies have reported on PHMG and ocular health, no studies have directly investigated its link to DED. Meanwhile, since humidifiers were often recommended for the treatment of DED, this study aimed to explore the potential role of PHMG-p, a component of humidifier disinfectants, in aggravating ocular surface damage and metabolic disorders.</p><p>In the present study, changes in conjunctival goblet cell (CGC) density and corneal inflammatory cytokines (IL-6, IL-1&#946;, and TNF-&#945;) were observed, aligning with previous findings. Several studies have investigated the relationship between DED and alterations in CGC numbers, emphasizing their critical role in maintaining tear film stability through mucin secretion. The loss of goblet cells has been strongly implicated in the pathogenesis of DED. Experimental mouse models of DED have demonstrated that DED induction promotes the migration of CD4<sup>+</sup> T cells and IFN-&#947;<sup>+</sup> cells into conjunctival goblet cell zones, leading to progressive goblet cell loss [<xref rid="B52-ijms-26-08660" ref-type="bibr">52</xref>]. This immune-mediated response contributes to tear film instability and ocular surface damage commonly observed in DED. More recently, a 2023 study utilized moxifloxacin-based fluorescence microscopy (MBFM) to noninvasively assess goblet cell changes in DED-induced mice [<xref rid="B53-ijms-26-08660" ref-type="bibr">53</xref>]. The results revealed a significant reduction in goblet cell density (GCD) and goblet cell area (GCA) in DED mice compared to controls, further supporting the role of goblet cell loss in DED progression [<xref rid="B53-ijms-26-08660" ref-type="bibr">53</xref>]. In our study, the number of conjunctival goblet cells (CGCs) was lower in the PHMG-p-treated group after DED induction compared to the DED group, except in the 0.3% PHMG-p only group. These findings confirm that PHMG-p exposure exacerbates DED. Notably, reduction in conjunctival goblet cell (CGC) was not as pronounced in the 0.3% PHMG-p only treated group compared to other groups is likely due to the strong cytotoxicity of high-dose PHMG-p, which may have suppressed immune cell activity. At higher concentrations, intense cytotoxic effects may have inhibited the immune response or induced early cell death, ultimately protecting goblet cells from immune-mediated damage. This finding suggests a concentration-dependent biphasic effect, where lower concentrations of PHMG-p may promote immune activation and inflammatory responses, while higher concentrations may lead to immune suppression and reduced inflammation, resulting in less goblet cell damage.</p><p>Additionally, several studies have established a strong association between DED and elevated levels of inflammatory cytokines, particularly IL-1&#946;, IL-6, and TNF-&#945;. These cytokines play a critical role in the pathogenesis and progression of DED, contributing to ocular surface inflammation and tear film instability. Research has consistently shown that IL-1&#946;, IL-6, and TNF-&#945; levels are significantly elevated in the tears and serum of DED patients compared to healthy controls [<xref rid="B16-ijms-26-08660" ref-type="bibr">16</xref>,<xref rid="B54-ijms-26-08660" ref-type="bibr">54</xref>,<xref rid="B55-ijms-26-08660" ref-type="bibr">55</xref>]. Furthermore, a meta-analysis by Roda et al. (2020) confirmed that DED patients exhibit higher levels of these pro-inflammatory cytokines, reinforcing their role in the chronic inflammatory state characteristic of DED [<xref rid="B55-ijms-26-08660" ref-type="bibr">55</xref>]. In our study, similar to previous studies, IL-1&#946;, IL-6, and TNF-&#945; levels tended to increase compared to the control group and were further elevated in the PHMG-p only group.</p><p>In our previous study, we identified biomarkers of DED through plasma and urinary metabolic profiling [<xref rid="B45-ijms-26-08660" ref-type="bibr">45</xref>]. Plasma and urine metabolic profiling provide valuable insights into biochemical processes and have significant applications in research and clinical settings. One of the key advantages of urine metabolic profiling is its non-invasive nature, making sample collection more convenient and patient-friendly [<xref rid="B56-ijms-26-08660" ref-type="bibr">56</xref>,<xref rid="B57-ijms-26-08660" ref-type="bibr">57</xref>]. Additionally, both plasma and urine contain metabolic signatures from various biochemical pathways, offering a holistic representation of an individual&#8217;s metabolic status [<xref rid="B58-ijms-26-08660" ref-type="bibr">58</xref>]. Another critical advantage of metabolic profiling is its role in biomarker discovery, enabling the identification of potential biomarkers for early disease detection, diagnosis, and prognosis [<xref rid="B56-ijms-26-08660" ref-type="bibr">56</xref>,<xref rid="B59-ijms-26-08660" ref-type="bibr">59</xref>,<xref rid="B60-ijms-26-08660" ref-type="bibr">60</xref>]. Furthermore, urine provides a broader metabolite coverage as it contains end-products from multiple organs, reflecting systemic metabolic changes more comprehensively [<xref rid="B56-ijms-26-08660" ref-type="bibr">56</xref>]. Also, urine samples exhibit high stability, making them ideal for metabolomic analysis [<xref rid="B61-ijms-26-08660" ref-type="bibr">61</xref>]. By offering a comprehensive and quantitative assessment of metabolic processes, plasma and urine metabolic profiling serve as powerful tools for advancing our understanding of human health, disease mechanisms, and therapeutic monitoring.</p><p>In our study, clearer clustering observed in the plasma PCA profile compared to the urinary NMR profile likely reflects inherent differences in biological variability and metabolic dynamics between these two matrices. Plasma provides a more immediate snapshot of systemic metabolic changes, especially in response to acute toxicological stress, such as PHMG-p exposure. In contrast, urine reflects a time-averaged excretory profile that is influenced by hydration status, renal function, and other confounding physiological factors, which may contribute to relatively blurred clustering. Nevertheless, urine remains a valuable biological matrix in metabolomics due to its non-invasive nature, wide metabolite coverage, and ability to capture cumulative metabolic alterations. In our findings, although plasma offered clearer group separation, urinary analysis still yielded meaningful insights&#8212;particularly in identifying overlapping pathways such as glutamate, glycine, and citrate metabolism. These complementary features underscore the advantage of integrating both plasma and urine profiles to enhance the overall interpretation of systemic toxicity.</p><p>Our findings confirmed that many metabolic pathways were shared between plasma and urinary metabolic profiling, with the following pathways being consistent: alanine metabolism, amino sugar metabolism, ammonia recycling, arginine and proline metabolism, aspartate metabolism, carnitine synthesis, the citric acid cycle, fatty acid biosynthesis, gluconeogenesis, the glucose-alanine cycle, glutamate metabolism, glycine and serine metabolism, ketone body metabolism, nicotinate and nicotinamide metabolism, transfer of acetyl groups into mitochondria, and the urea cycle (<xref rid="ijms-26-08660-t001" ref-type="table">Table 1</xref> and <xref rid="ijms-26-08660-t002" ref-type="table">Table 2</xref>). Among these, the metabolic pathways associated with DED include arginine and proline metabolism, the citric acid cycle, glutamate metabolism, and glycine and serine metabolism, among others, which will be discussed in detail below [<xref rid="B42-ijms-26-08660" ref-type="bibr">42</xref>,<xref rid="B47-ijms-26-08660" ref-type="bibr">47</xref>]. Notably, among the pathways related to dry eye disease, glutathione metabolism was the only one that differed between plasma and urine.</p><p>For the plasma and urinary metabolites arginine, glutamate, glutamine, glycine, and pyruvate, their involvement in pathways such as arginine and proline metabolism, glutamate metabolism, glycine and serine metabolism, and the urea cycle has been confirmed. These metabolites show a significant correlation with inflammatory cytokines, including TNF-&#945;, IL-6, and IL-1&#946;. In the current study, glutamine and glutamate was upregulated in PHMG-p treated group in both plasma or urine (<xref rid="ijms-26-08660-f006" ref-type="fig">Figure 6</xref> and <xref rid="ijms-26-08660-f009" ref-type="fig">Figure 9</xref>). Glutamine plays a vital role in regulating inflammatory responses by supporting lymphocyte proliferation and cytokine production, making it essential for immune homeostasis. Studies have shown that glutamine supplementation reduces pro-inflammatory cytokine levels in the gut mucosa, including IL-1&#946;, IL-6, and TNF-&#945;, suggesting that glutamine availability can modulate immune activation and inflammatory pathways, contributing to a more controlled immune response [<xref rid="B62-ijms-26-08660" ref-type="bibr">62</xref>]. In contrast, elevated extracellular glutamate levels have been linked to increased inflammation, particularly through neuroimmune interactions. Inflammatory processes can cause glutamate spillover into the extrasynaptic space, often as a result of glial dysfunction. This excess glutamate further exacerbates immune responses by activating microglial receptors, leading to the release of pro-inflammatory cytokines, such as TNF-&#945; and IL-1&#946; [<xref rid="B63-ijms-26-08660" ref-type="bibr">63</xref>]. These findings highlight the dual role of glutamine and glutamate in inflammatory regulation, with glutamine acting as an anti-inflammatory agent, while excessive glutamate contributes to neuroinflammation and cytokine activation. Additionally, glutamate metabolism plays a critical role in inflammation and oxidative stress. Since glutamine can be converted to glutamate, it has been identified as an anti-inflammatory agent by inhibiting the production of reactive oxygen species (ROS), nitric oxide synthase (NOS), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), all of which are key mediators of inflammation [<xref rid="B63-ijms-26-08660" ref-type="bibr">63</xref>]. Furthermore, glutamine suppresses NF-&#954;B activation and inhibits the phosphorylation of STAT1, STAT5, and Akt, leading to reduced levels of TNF-&#945; and IFN-&#947; [<xref rid="B64-ijms-26-08660" ref-type="bibr">64</xref>]. However, at high concentrations, glutamate can induce oxidative stress and apoptosis in cerebral vascular endothelial cells, contributing to neuroinflammation and vascular damage [<xref rid="B65-ijms-26-08660" ref-type="bibr">65</xref>]. These findings underscore the complex role of glutamate metabolism in inflammation, balancing both protective and detrimental effects depending on its concentration and metabolic context.</p><p>Glycine exhibits a significant anti-inflammatory effect by modulating the production and activity of pro-inflammatory cytokines, particularly TNF-&#945;, IL-6, and IL-1&#946;. Studies have demonstrated that glycine inhibits the production of these cytokines in various cell types and tissues, thereby contributing to the suppression of inflammatory responses [<xref rid="B66-ijms-26-08660" ref-type="bibr">66</xref>,<xref rid="B67-ijms-26-08660" ref-type="bibr">67</xref>]. This reduction in pro-inflammatory cytokine levels plays a crucial role in mitigating systemic inflammation, highlighting glycine&#8217;s potential as a therapeutic agent for inflammatory conditions. Beyond its anti-inflammatory properties, glycine is actively involved in glycine and serine metabolism, which is essential for immune regulation and cellular function. One of glycine&#8217;s key mechanisms in inflammation control is its ability to reduce calcium influx in macrophages, thereby inhibiting the production of toxic free radicals and ultimately reducing oxidative stress and tissue damage [<xref rid="B64-ijms-26-08660" ref-type="bibr">64</xref>]. According to our study results, glycine levels were upregulated in all experimental groups compared to the control in plasma, and showed an increasing trend in urine, except in the PHMG-p 0.3% group (<xref rid="ijms-26-08660-f006" ref-type="fig">Figure 6</xref> and <xref rid="ijms-26-08660-f009" ref-type="fig">Figure 9</xref>). This suggests that glycine levels may have increased in response to suppress the elevation of inflammatory cytokines TNF-&#945;, IL-6, and IL-1&#946;. These findings indicate that glycine and serine metabolism not only regulate inflammatory pathways but also contribute to disease progression in various pathological conditions, including immune-related disorders.</p><p>Pyruvate levels were up-regulated in the plasma after DED induction in the high-dose PHMG-p group and in the PHMG-p only group (<xref rid="ijms-26-08660-f006" ref-type="fig">Figure 6</xref>). Pyruvate levels typically increase during inflammation and oxidative stress, representing a metabolic adaptation to cellular stress. This elevation is associated with several protective mechanisms, as pyruvate and lactate contribute to oxidative stress resistance by inducing a mild hormetic increase in reactive oxygen species (ROS). This transient ROS surge activates antioxidant defenses and pro-survival pathways, ultimately enhancing cellular protection [<xref rid="B68-ijms-26-08660" ref-type="bibr">68</xref>]. Additionally, pyruvate supplementation has been shown to suppress mitochondrial ROS generation and maintain mitochondrial membrane potential under oxidative stress conditions, highlighting mitochondria as key targets of pyruvate&#8217;s protective effects [<xref rid="B69-ijms-26-08660" ref-type="bibr">69</xref>]. The rise in pyruvate levels during inflammation and oxidative stress may serve a protective function by modulating mitochondrial activity and maintaining redox balance, ultimately supporting cell survival and adaptation [<xref rid="B68-ijms-26-08660" ref-type="bibr">68</xref>,<xref rid="B69-ijms-26-08660" ref-type="bibr">69</xref>]. These findings suggest that pyruvate plays a critical role in cellular defense mechanisms against oxidative damage. Beyond its role in oxidative stress regulation, pyruvate is a key player in immune cell metabolism. Although not directly part of the TCA cycle, pyruvate serves as a crucial metabolic intermediary that influences immune cell activation and function. In activated immune cells, pyruvate is preferentially converted to lactate rather than entering the TCA cycle, a metabolic shift that supports immune cell activation and proliferation by facilitating glycolytic reprogramming [<xref rid="B70-ijms-26-08660" ref-type="bibr">70</xref>]. However, a portion of pyruvate can still enter the TCA cycle to produce citrate, which is then exported to the cytosol to participate in immune-related functions, such as lipid biosynthesis and inflammatory signaling [<xref rid="B71-ijms-26-08660" ref-type="bibr">71</xref>].</p><p>In our study, arginine levels were increased in plasma across all experimental groups (<xref rid="ijms-26-08660-f006" ref-type="fig">Figure 6</xref>). Arginine plays a crucial role in the urea cycle and nitric oxide (NO) production, making it an essential component in inflammation and oxidative stress regulation [<xref rid="B64-ijms-26-08660" ref-type="bibr">64</xref>]. The urea cycle is closely linked to arginine metabolism, as it facilitates nitrogen excretion while also contributing to NO synthesis, which has significant implications for immune function and vascular homeostasis [<xref rid="B64-ijms-26-08660" ref-type="bibr">64</xref>]. During inflammatory responses, macrophage M1 polarization promotes the expression of inducible nitric oxide synthase (iNOS), which utilizes arginine to generate NO. This process enhances the antimicrobial and immunomodulatory effects of macrophages while also inhibiting reactive oxygen species (ROS) activity, thereby influencing redox balance and inflammatory signaling [<xref rid="B64-ijms-26-08660" ref-type="bibr">64</xref>]. Furthermore, arginine is synthesized from glutamine, glutamate, and proline via the intestinal-renal axis, highlighting its interconnected role in multiple metabolic pathways. Beyond its involvement in NO synthesis, arginine also contributes to creatine biosynthesis and methylation reactions, both of which are critical for maintaining cellular homeostasis and metabolic regulation [<xref rid="B72-ijms-26-08660" ref-type="bibr">72</xref>].</p><p>The urea cycle is closely linked to inflammatory response, immune regulation, and oxidative stress, playing a critical role in maintaining metabolic and immune homeostasis. Disruptions in the urea cycle, such as urea cycle disorders (UCDs), can lead to hyperammonemia, which negatively affects immune cell function, particularly T cells and macrophages [<xref rid="B73-ijms-26-08660" ref-type="bibr">73</xref>]. Additionally, elevated levels of certain amino acids, including glutamine, glycine, and alanine, in UCDs may influence T and B cell activity, further impacting immune function [<xref rid="B73-ijms-26-08660" ref-type="bibr">73</xref>]. In our study, glutamine and glycine were increased in both plasma and urine, whereas alanine tended to increase only in plasma (<xref rid="ijms-26-08660-f006" ref-type="fig">Figure 6</xref> and <xref rid="ijms-26-08660-f009" ref-type="fig">Figure 9</xref>). Beyond its metabolic role, the urea cycle is essential for proper immune responses, particularly in T-cell function. UCDs have been associated with significant immune dysfunctions, including impaired T-cell proliferation [<xref rid="B73-ijms-26-08660" ref-type="bibr">73</xref>]. Arginine, a key intermediate in the urea cycle, is critical for T-cell activation and function, and its depletion can lead to increased susceptibility to infections [<xref rid="B73-ijms-26-08660" ref-type="bibr">73</xref>].</p><p>The citric acid cycle (TCA cycle) plays a fundamental role in cellular metabolism and has significant implications for inflammation, immune responses, and oxidative stress regulation. Beyond its primary function in energy production, key metabolic intermediates such as citrate, succinate, and 2-oxoglutarate act as critical signaling molecules that influence immune cell function and inflammatory processes. In our study, the plasma metabolites associated with the citric acid cycle were citrate, pyruvate, and succinate, while the urinary metabolites included cis-aconitate, citrate, 2-oxoglutarate, and succinate. All plasma metabolites showed an increase, whereas in urine, citrate, 2-oxoglutarate, and succinate exhibited an increasing trend in the PHMG-p treatment groups (<xref rid="ijms-26-08660-f006" ref-type="fig">Figure 6</xref> and <xref rid="ijms-26-08660-f009" ref-type="fig">Figure 9</xref>). Among these metabolites, citrate has emerged as a key immunometabolite, exerting multiple effects on inflammation and immune regulation. In pro-inflammatory macrophages, citrate accumulation promotes the production of inflammatory mediators, including prostaglandins, nitric oxide (NO), and reactive oxygen species (ROS), which further amplify immune responses [<xref rid="B70-ijms-26-08660" ref-type="bibr">70</xref>,<xref rid="B74-ijms-26-08660" ref-type="bibr">74</xref>]. Additionally, cytosolic citrate serves as a precursor for acetyl-CoA, which plays a crucial role in histone acetylation and epigenetic regulation, thereby influencing the expression of inflammatory genes [<xref rid="B74-ijms-26-08660" ref-type="bibr">74</xref>]. Furthermore, citrate is essential for lipid biosynthesis, a process necessary for membrane expansion in macrophages and dendritic cells, which supports antigen presentation and cytokine production [<xref rid="B71-ijms-26-08660" ref-type="bibr">71</xref>]. These findings highlight citrate&#8217;s dual role as both a metabolic substrate and a regulatory molecule in immune responses. Similarly, succinate accumulation in activated immune cells has profound effects on inflammatory signaling. One of its key functions is stabilizing hypoxia-inducible factor 1&#945; (HIF-1&#945;), which enhances the expression of pro-inflammatory genes, thereby promoting immune activation [<xref rid="B75-ijms-26-08660" ref-type="bibr">75</xref>]. Additionally, succinate oxidation by succinate dehydrogenase (SDH) drives mitochondrial ROS production, further amplifying inflammation and immune cell activation [<xref rid="B76-ijms-26-08660" ref-type="bibr">76</xref>]. These findings underscore succinate&#8217;s role as a key regulator of metabolic reprogramming in immune cells. 2-Oxoglutarate also plays a crucial role in immune cell regulation and metabolic sensing. It serves as a co-substrate for demethylases, influencing epigenetic modifications that govern immune cell differentiation and function [<xref rid="B77-ijms-26-08660" ref-type="bibr">77</xref>]. Additionally, changes in the isocitrate-to-&#945;-ketoglutarate ratio in pro-inflammatory macrophages serve as metabolic indicators of immune activation [<xref rid="B70-ijms-26-08660" ref-type="bibr">70</xref>]. This suggests that 2-oxoglutarate is involved in both cellular adaptation to metabolic stress and the regulation of inflammatory responses. Overall, the Citric Acid Cycle and its intermediates play a critical role in orchestrating immune responses, inflammation, and oxidative stress regulation. These metabolites not only provide energy and biosynthetic precursors, but also function as signaling molecules that mediate metabolic reprogramming in immune cells, further influencing inflammatory and immune regulatory pathways.</p><p>Glutathione (GSH) metabolism, which occurs specifically in plasma, involves amino acids such as glycine, glutamate, and alanine and plays a crucial role in regulating inflammation, modulating immune responses, and protecting against oxidative stress. In our study, the levels of glycine, glutamate, and alanine tended to increase in the PHMG-p treatment group (<xref rid="ijms-26-08660-f006" ref-type="fig">Figure 6</xref> and <xref rid="ijms-26-08660-f009" ref-type="fig">Figure 9</xref>). GSH metabolism plays a critical role in regulating inflammatory responses, immune function, and oxidative stress, serving as a key antioxidant and modulator of immune cell activity. The relationship between GSH and these processes is complex, as it influences cytokine production, cell survival, and redox balance. GSH plays an essential role in modulating pro-inflammatory cytokine production in response to pathogens. Intracellular GSH levels directly regulate the release of cytokines, and GSH depletion has been shown to partially suppress pro-inflammatory responses to certain stimuli, indicating its role in immune activation [<xref rid="B78-ijms-26-08660" ref-type="bibr">78</xref>]. Additionally, GSH contributes to cell survival in monocytes exposed to inflammatory stimuli, highlighting its importance in maintaining immune cell function under inflammatory conditions [<xref rid="B78-ijms-26-08660" ref-type="bibr">78</xref>]. These findings suggest that GSH is not only a protective antioxidant but also a key regulator of immune homeostasis. Beyond its role in inflammation, GSH is a major cellular antioxidant, crucial for buffering reactive oxygen species (ROS) generated during immune cell activation. By neutralizing ROS, GSH prevents oxidative damage to immune cells and other cellular components, ensuring proper immune function and cellular integrity [<xref rid="B79-ijms-26-08660" ref-type="bibr">79</xref>]. These findings underscore the essential role of GSH in controlling oxidative stress and inflammation, making it a potential target for therapeutic interventions in inflammatory and oxidative stress-related diseases.</p><p>In conclusion, this study demonstrates that exposure to PHMG-p exacerbates DED by promoting inflammatory responses on the ocular surface. Metabolomic profiling identified distinct metabolic alterations in plasma and urine, particularly in pathways related to glutamate metabolism, glycine and serine metabolism, arginine and proline metabolism, glutathione metabolism, and the citric acid cycle. These metabolic changes correlated with elevated levels of pro-inflammatory cytokines (IL-1&#946;, IL-6, and TNF-&#945;) in corneal and lacrimal gland tissues, reinforcing the role of inflammation in PHMG-p-induced ocular toxicity. Furthermore, glutamate and glycine levels were significantly elevated in both plasma and urine, suggesting their involvement in immune regulation and oxidative stress. The observed increase in pyruvate, succinate, and citrate highlights the role of metabolic reprogramming in inflammatory processes. Notably, arginine levels were elevated in plasma, supporting its role in nitric oxide (NO) production and immune modulation. These findings underscore the potential risks of PHMG-p exposure on ocular health, particularly for individuals using humidifiers in environments prone to DED. Additionally, the metabolomic insights provided in this study contribute to a deeper understanding of DED pathophysiology, offering new perspectives for biomarker discovery and targeted therapeutic strategies.</p></sec><sec id="sec4-ijms-26-08660"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-26-08660"><title>4.1. Chemicals</title><p>Polyhexamethylene guanidine phosphate (PHMG-p, 25%) was obtained from SK Chemicals (Seoul, Republic of Korea). Scopolamine hydrobromide, 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) and 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium salt (TSP) were obtained from Sigma Aldrich (St. Louis, MO, USA). Sodium azide was purchased from Bio Basic Inc. (Markham, ON, Canada).</p></sec><sec sec-type="methods" id="sec4dot2-ijms-26-08660"><title>4.2. In Vivo Animal Study Design and Experimental Procedures</title><p>Forty-two male Sprague Dawley (S-D) rats (7 weeks old, weighing 200&#8211;240 g) were purchased from Samtako Co. (Osan, Republic of Korea). The experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Dankook University (IACUC approval number: 2017-035). All animals were acclimatized for one week under controlled environmental conditions: a 12-h light/dark cycle (lights on from 06:00 to 18:00), ambient temperature maintained at 20&#8211;24 &#176;C, and relative humidity at 30% &#177; 5%. During the acclimatization and experimental periods, standard laboratory chow (LabDiet 5L79, Orientbio Inc., Seongnam, Republic of Korea) and tap water were provided ad libitum. The rats were randomly divided into seven groups (<italic toggle="yes">n</italic> = 6 per group). Group 1 served as the untreated control. Groups 2 to 5 were assigned as dry eye disease (DED) induction groups. DED was induced by subcutaneous (SC) injection of scopolamine hydrobromide at a dose of 3 mg/kg (total 12 mg/day), administered four times daily at 9:00, 12:00, 15:00, and 18:00 for 13 consecutive days. In addition to pharmacological induction, animals in these groups were exposed to desiccating environmental stress by housing them in a dry eye chamber for 18 h per day (from 16:00 to 10:00 the following day), followed by 6 h outside the chamber [<xref rid="B80-ijms-26-08660" ref-type="bibr">80</xref>,<xref rid="B81-ijms-26-08660" ref-type="bibr">81</xref>,<xref rid="B82-ijms-26-08660" ref-type="bibr">82</xref>,<xref rid="B83-ijms-26-08660" ref-type="bibr">83</xref>,<xref rid="B84-ijms-26-08660" ref-type="bibr">84</xref>]. In the positive control (PC) group (Group 3), 0.1% benzalkonium chloride (BAC) in phosphate-buffered saline (PBS) was topically instilled into both eyes once daily at 15:00, with a total of 12 applications per session at 5-min intervals, in addition to scopolamine administration and chamber exposure. Groups 4 and 5 followed the same scopolamine and desiccation regimen as Group 2, but instead received topical PHMG-p at concentrations of 0.1% and 0.3%, respectively, applied using the same method and schedule as BAC in Group 3. Groups 6 and 7 were treated with PHMG-p alone at 0.1% and 0.3%, respectively, following the same topical application schedule and environmental exposure as the other groups. To confirm successful DED induction, diagnostic assessments were conducted on day 8 of scopolamine administration. These included measurement of tear volume, tear film break-up time (TBUT), and microscopic examination of the ocular surface. On day 14, after completion of all treatments, the same diagnostic parameters were evaluated to assess the therapeutic or aggravating effects of the interventions. Final assessments included tear volume, corneal fluorescein staining scores, and TBUT. At the end of the experiment, rats were euthanized for tissue and biofluid collection. Eyeballs were carefully removed for histological evaluation. Urine samples were collected overnight in metabolic cages following the final scopolamine administration. Each urine sample was collected into a glass bottle containing 50 &#181;L of 3% sodium azide. Blood samples were obtained via the abdominal aorta under CO<sub>2</sub> anesthesia using an 18-gauge needle, and centrifuged at 3000&#215; <italic toggle="yes">g</italic> for 15 min at 4 &#176;C to separate plasma. All urine and plasma samples were stored at &#8722;70 &#176;C until further analysis.</p></sec><sec id="sec4dot3-ijms-26-08660"><title>4.3. Clinical Evaluation of Animal Models</title><p>Tear volume was measured using phenol red-impregnated cotton threads (Zone-Quick, Glendora, CA, USA). The threads were gently placed at the lateral canthus of each eye using fine forceps and removed after 20 s. The wetted length of the thread, which turned red upon contact with tears, was measured under a microscope and expressed in mm [<xref rid="B82-ijms-26-08660" ref-type="bibr">82</xref>]. The measured length was converted to tear volume based on the manufacturer&#8217;s instructions. Tear break-up time (TBUT) was assessed to evaluate tear film stability. A 1% sodium fluorescein solution was instilled into both eyes of non-anesthetized rats, and the time until the appearance of dry spots on the corneal surface after blinking was measured under cobalt blue light. The average of three repeated measurements was recorded as the TBUT. Corneal fluorescein staining was performed to assess epithelial damage. A 5% fluorescein solution was applied to the conjunctival sac, and eyes were examined under a cobalt blue light using a slit-lamp biomicroscope. Corneal damage was scored from 0 to 4 according to the severity of clinical signs, including conjunctival congestion, secretions, conjunctival edema, or edema of the eyelids.</p></sec><sec id="sec4dot4-ijms-26-08660"><title>4.4. Histological and Histochemical Analysis</title><p>Hematoxylin and eosin (H&amp;E) staining was performed for general morphological evaluation. Whole eyes were surgically excised, fixed in 4% formalin, and embedded in optimal cutting temperature (O.C.T.) compound (Tissue-Tek, Sakura, Tokyo, Japan). Corneal and conjunctival tissues were cryosectioned at a thickness of 5 &#956;m using a cryomicrotome, and stained with H&amp;E. Stained sections were imaged using a virtual microscope system. Periodic acid&#8211;Schiff (PAS) staining was conducted to detect goblet cell. Cryosectioned tissues (5 &#956;m) were treated with 0.5% periodic acid (Sigma&#8211;Aldrich, Inc, St. Louis, MO, USA, PAS kit.) for 5 min, rinsed with distilled water, and incubated with Schiff&#8217;s reagent for 30 min at room temperature. After washing under running water for 5 min, the sections were counterstained with hematoxylin for 3 min, dehydrated, cleared, and mounted. Digital images of the stained tissues were obtained using a virtual microscope.</p></sec><sec id="sec4dot5-ijms-26-08660"><title>4.5. Immunohistochemistry (IHC)</title><p>Tissue slides were fixed in acetone for 15 min and then blocked with 5% bovine serum albumin (BSA) (Albumin, Bioshop Canada Inc., Burlington, ON, Canada) in PBS for 1 h at room temperature. Primary antibodies against IL-1&#946; (Abcam, Cambridge, UK; ab9722), IL-6 (AbPRONTIER, Seoul, Republic of Korea; YF-MA10477), and TNF-&#945; (Abcam, Cambridge, UK; ab199013), each diluted 1:200 in 5% BSA, were applied and incubated overnight at 4 &#176;C. After three washes in PBS (5 min each), enzyme-conjugated secondary antibodies diluted in 5% BSA were applied for 1 h at room temperature. Following another round of PBS washing, 2.5 mL of 5% BSA containing reagents A and B from the ABC kit (VECTASTAIN Elite ABC HRP Kit, Vector Laboratories, Inc., Burlingame, CA, USA; Cat. No: PK-6100) was added and incubated for 30 min. After washing with PBS for 5 min, a drop of buffer stock solution, a drop of 3,3&#8242;-diaminobenzidine (DAB) stock buffer, and 25 &#956;L hydrogen peroxide solution of the DAB Substrate Kit (DAB Peroxidase Substrate, Vector Laboratories, Inc., 30 Ingold Road, Burlingame, CA, USA; Cat. No: SK-4100) were added to 2.5 mL 5% BSA in PBS until a browning reaction appeared. The sections were counterstained with Mayer&#8217;s hematoxylin (Sigma-Aldrich, Inc, St. Louis, MO, USA) for 30 s and imaged using a virtual microscope.</p></sec><sec id="sec4dot6-ijms-26-08660"><title>4.6. <sup>1</sup>H NMR-Based Metabolomics Analysis</title><p>After thawing the plasma samples at 4 &#176;C, a 350 &#956;L aliquot was transferred into a microcentrifuge tube containing 350 &#956;L of deuterated water (D<sub>2</sub>O) solution with 4 mM TSP as an internal standard for chemical shift referencing. Urine samples were also thawed at 4 &#176;C and centrifuged to remove particulates. A 600 &#956;L aliquot of the urine supernatant was added to a microcentrifuge tube containing 70 &#956;L of D<sub>2</sub>O solution supplemented with 5 mM DSS and 100 mM imidazole. In addition, 30 &#956;L of 0.42% sodium azide was added to each urine sample to prevent microbial growth. Following vortex mixing, all samples were subjected to <sup>1</sup>H-NMR analysis within 48 h. NMR spectra were acquired using a Varian Unity Inova 600 MHz spectrometer (Agilent Technologies, Santa Clara, CA, USA) operating at 26&#176;C, located at Pusan National University (Busan, Republic of Korea). The Carr&#8211;Purcell&#8211;Meiboom&#8211;Gill (CPMG) pulse sequence was applied to attenuate signals from macromolecules and residual water. For urine samples, spectra were acquired using the following parameters: a 16.2 &#956;s 90&#176; pulse width, a 3 s relaxation delay, a 3 s acquisition time, and a total acquisition time of 13 min and 9 s. For plasma samples, the acquisition was performed using a 16.5 &#956;s 90&#176; pulse width, a 3 s relaxation delay, a 3 s acquisition time, and a total acquisition time of 13 min and 20 s. All spectra were acquired with 128 scans and a spectral width of 24,038.5 Hz. Spectral data were processed using the Chenomx NMR Suite software (version 8.3, Chenomx Inc., Edmonton, AB, Canada). The spectral region from &#948; 0.0 to 10.0 ppm was divided into bins with a width of 0.04 ppm, yielding a total of 250 integrated regions per spectrum. This binning procedure generated a normalized intensity distribution across 250 variables for each spectrum, which was used for subsequent pattern recognition analysis. The water resonance region (&#948; 4.5&#8211;5.0 ppm) was excluded from the analysis to minimize variability associated with differences in water suppression efficiency. Metabolite identification and quantification were also performed using the Chenomx NMR Suite Professional software (version 8.3). TSP (2 mM) and DSS (0.5 mM) were used as the chemical shift and concentration references for plasma and urine samples, respectively.</p></sec><sec id="sec4dot7-ijms-26-08660"><title>4.7. Multivariate and Statistical Analysis</title><p>All NMR spectral data were exported from the Chenomx NMR Suite Professional software into Microsoft Excel (*.xls) format. The one-dimensional NMR data were then imported into SIMCA-P software (version 12.0, Umetrics Inc., Kinnelon, NJ, USA) for multivariate statistical analysis to explore intrinsic variations in the dataset. Prior to analysis, the data were center-scaled. PCA and OPLS-DA were performed, and the resulting score plots were used to visualize the distribution and clustering of samples across groups. Additionally, VIP values from the OPLS-DA model were used to identify potential biomarkers associated with PHMG-p exposure in the DED model. For univariate analysis, the means and standard deviations of each metabolite were calculated using Microsoft Excel (version 2019). Quantitative differences in plasma and urinary metabolite concentrations among experimental groups were assessed using ANOVA test in GraphPad Prism (version 5.01, San Diego, CA, USA). A <italic toggle="yes">p</italic>-value of &lt; 0.05 was considered statistically significant.</p></sec></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>J.D.L. drafted the manuscript; J.D.L., S.B.O. and H.G. performed the animal experiments; J.D.L., S.B.O. and H.G. conducted sample isolation and histopathological evaluation. H.Y.K. performed statistical analyses; S.K. and H.Y.K. analyzed the biological samples using <sup>1</sup>H-NMR spectroscopy; K.J.C. and K.-B.K. designed the study; G.-W.H. and K.-B.K. revised and finalized the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Institutional guidelines for the care and use of animals were followed and the experimental protocol was approved by the Institutional Animal Care and Use Committee of Dankook University (IACUC, Approval Date: 12 September 2017, Approval number: 2017-035). All procedures involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors have no conflicts of interest to disclose.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><sup>1</sup>H-NMR</td><td align="left" valign="middle" rowspan="1" colspan="1">Proton nuclear magnetic resonance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ANOVA</td><td align="left" valign="middle" rowspan="1" colspan="1">Analysis of variance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BAC</td><td align="left" valign="middle" rowspan="1" colspan="1">Benzalkonium chloride</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Bovine serum albumin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COX-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclooxygenase-2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DED</td><td align="left" valign="middle" rowspan="1" colspan="1">Dry eye disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GLS1</td><td align="left" valign="middle" rowspan="1" colspan="1">Glutaminase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GSH</td><td align="left" valign="middle" rowspan="1" colspan="1">Glutathione</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-1&#946;</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin-1 beta</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-6</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin-6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">iNOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Inducible nitric oxide synthase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NO</td><td align="left" valign="middle" rowspan="1" colspan="1">Nitric oxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OPLS-DA</td><td align="left" valign="middle" rowspan="1" colspan="1">Orthogonal projections to latent structures discriminant analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OSDI</td><td align="left" valign="middle" rowspan="1" colspan="1">Ocular Surface Disease Index</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCA</td><td align="left" valign="middle" rowspan="1" colspan="1">Principal component analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PHMG-p</td><td align="left" valign="middle" rowspan="1" colspan="1">Polyhexamethylene guanidine phosphate.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">Reactive oxygen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCA cycle</td><td align="left" valign="middle" rowspan="1" colspan="1">Citric acid cycle</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#945;</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor necrosis factor-alpha</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VIP</td><td align="left" valign="middle" rowspan="1" colspan="1">Variable importance in projection</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-ijms-26-08660"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Golden</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zeppieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B.C.</given-names></name></person-group><article-title>Dry Eye Syndrome</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470411/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK470411/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-21">(accessed on 21 March 2025)</date-in-citation><pub-id pub-id-type="pmid">29262012</pub-id></element-citation></ref><ref id="B2-ijms-26-08660"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siemasko</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Beuerman</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Pflugfelder</surname><given-names>S.C.</given-names></name></person-group><article-title>The Role of the Lacrimal Functional Unit in the Pathophysiology of Dry Eye</article-title><source>Exp. Eye Res.</source><year>2004</year><volume>78</volume><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2003.09.003</pub-id><pub-id pub-id-type="pmid">15106920</pub-id></element-citation></ref><ref id="B3-ijms-26-08660"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honavar</surname><given-names>S.G.</given-names></name></person-group><article-title>Dry Eye Disease = DED = A Disease Eluding Diagnosis</article-title><source>Indian J. Ophthalmol.</source><year>2023</year><volume>71</volume><fpage>1059</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.4103/IJO.IJO_796_23</pub-id><pub-id pub-id-type="pmid">37026229</pub-id><pub-id pub-id-type="pmcid">PMC10276706</pub-id></element-citation></ref><ref id="B4-ijms-26-08660"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bravo</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>J.A.C.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>P.A.</given-names></name></person-group><article-title>Short-term Health Effects of Tear Agents Chlorobenzylidenemalonitrile and Oleoresin Capsicum During the Civil Riots of Santiago de Chile in 2019&#8211;2020</article-title><source>Toxicol. Res.</source><year>2025</year><volume>41</volume><fpage>291</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1007/s43188-025-00282-3</pub-id><pub-id pub-id-type="pmid">40291112</pub-id><pub-id pub-id-type="pmcid">PMC12022201</pub-id></element-citation></ref><ref id="B5-ijms-26-08660"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inomata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwagami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hiratsuka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name></person-group><article-title>Maximum Blink Interval Is Associated with Tear Film Breakup Time: A New Simple, Screening Test for Dry Eye Disease</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>13443</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-31814-7</pub-id><pub-id pub-id-type="pmid">30194447</pub-id><pub-id pub-id-type="pmcid">PMC6128834</pub-id></element-citation></ref><ref id="B6-ijms-26-08660"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Research Subcommittee of the International Dry Eye WorkShop</collab></person-group><article-title>Research in Dry Eye: Report of the Research Subcommittee of the International Dry Eye WorkShop</article-title><source>Ocul. Surf.</source><year>2007</year><volume>5</volume><fpage>179</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/S1542-0124(12)70086-1</pub-id><pub-id pub-id-type="pmid">17508121</pub-id></element-citation></ref><ref id="B7-ijms-26-08660"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Si</surname><given-names>H.</given-names></name></person-group><article-title>Evaluation of a Novel Dry Eye Model Induced by Oral Administration of Finasteride</article-title><source>Mol. Med. Rep.</source><year>2017</year><volume>16</volume><fpage>8763</fpage><lpage>8770</lpage><pub-id pub-id-type="doi">10.3892/mmr.2017.7754</pub-id><pub-id pub-id-type="pmid">29039509</pub-id><pub-id pub-id-type="pmcid">PMC5779951</pub-id></element-citation></ref><ref id="B8-ijms-26-08660"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brignole</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pisella</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Goldschild</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Saint Jean</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goguel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baudouin</surname><given-names>C.</given-names></name></person-group><article-title>Flow Cytometric Analysis of Inflammatory Markers in Conjunctival Epithelial Cells of Patients with Dry Eyes</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2000</year><volume>41</volume><fpage>1356</fpage><lpage>1363</lpage><pub-id pub-id-type="pmid">10798650</pub-id></element-citation></ref><ref id="B9-ijms-26-08660"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narayanan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>A.M.</given-names></name></person-group><article-title>Conjunctival Cytokine Expression in Symptomatic Moderate Dry Eye Subjects</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2006</year><volume>47</volume><fpage>2445</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1167/iovs.05-1364</pub-id><pub-id pub-id-type="pmid">16723455</pub-id></element-citation></ref><ref id="B10-ijms-26-08660"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baudouin</surname><given-names>C.</given-names></name></person-group><article-title>The Pathology of Dry Eye</article-title><source>Surv. Ophthalmol.</source><year>2001</year><volume>45</volume><fpage>S211</fpage><lpage>S220</lpage><pub-id pub-id-type="doi">10.1016/S0039-6257(00)00200-9</pub-id><pub-id pub-id-type="pmid">11587145</pub-id></element-citation></ref><ref id="B11-ijms-26-08660"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Pflugfelder</surname><given-names>S.C.</given-names></name></person-group><article-title>Inflammation in Dry Eye</article-title><source>Ocul. Surf.</source><year>2004</year><volume>2</volume><fpage>124</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/S1542-0124(12)70148-9</pub-id><pub-id pub-id-type="pmid">17216083</pub-id></element-citation></ref><ref id="B12-ijms-26-08660"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>I.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.Y.</given-names></name></person-group><article-title>Interleukin-6 and Tumor Necrosis Factor-Alpha Levels in Tears of Patients with Dry Eye Syndrome</article-title><source>Cornea</source><year>2007</year><volume>26</volume><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1097/ICO.0b013e31803dcda2</pub-id><pub-id pub-id-type="pmid">17457192</pub-id></element-citation></ref><ref id="B13-ijms-26-08660"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pflugfelder</surname><given-names>S.C.</given-names></name></person-group><article-title>Stimulation of Matrix Metalloproteinases by Hyperosmolarity via a JNK Pathway in Human Corneal Epithelial Cells</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2004</year><volume>45</volume><fpage>4302</fpage><lpage>4311</lpage><pub-id pub-id-type="doi">10.1167/iovs.04-0299</pub-id><pub-id pub-id-type="pmid">15557436</pub-id></element-citation></ref><ref id="B14-ijms-26-08660"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Pflugfelder</surname><given-names>S.C.</given-names></name></person-group><article-title>JNK and ERK MAP Kinases Mediate Induction of IL-1&#946;, TNF-&#945; and IL-8 Following Hyperosmolar Stress in Human Limbal Epithelial Cells</article-title><source>Exp. Eye Res.</source><year>2006</year><volume>82</volume><fpage>588</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">16202406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exer.2005.08.019</pub-id><pub-id pub-id-type="pmcid">PMC2198933</pub-id></element-citation></ref><ref id="B15-ijms-26-08660"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelagere</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Scholand</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>DeJong</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Astley</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Callegan</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Bowdish</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Makarenkova</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>de Paiva</surname><given-names>C.S.</given-names></name></person-group><article-title>TNF Is a Critical Cytokine in Age-Related Dry Eye Disease</article-title><source>Ocul. Surf.</source><year>2023</year><volume>30</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.jtos.2023.08.004</pub-id><pub-id pub-id-type="pmid">37634571</pub-id><pub-id pub-id-type="pmcid">PMC10812879</pub-id></element-citation></ref><ref id="B16-ijms-26-08660"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name></person-group><article-title>Analyze Interleukin-1&#946;, Interleukin-6, and Tumor Necrosis Factor-Alpha Levels in Dry Eye and the Therapeutic Effect of Cyclosporine A</article-title><source>World J. Clin. Cases</source><year>2024</year><volume>12</volume><fpage>5665</fpage><lpage>5672</lpage><pub-id pub-id-type="doi">10.12998/wjcc.v12.i25.5665</pub-id><pub-id pub-id-type="pmid">39247746</pub-id><pub-id pub-id-type="pmcid">PMC11263063</pub-id></element-citation></ref><ref id="B17-ijms-26-08660"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.K.</given-names></name></person-group><article-title>Neutralization of Ocular Surface TNF-Alpha Reduces Ocular Surface and Lacrimal Gland Inflammation Induced by In Vivo Dry Eye</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2013</year><volume>54</volume><fpage>7557</fpage><lpage>7566</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-11515</pub-id><pub-id pub-id-type="pmid">24052636</pub-id></element-citation></ref><ref id="B18-ijms-26-08660"><label>18.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>HIRA (Health Insurance Review and Assessment Service)</collab></person-group><article-title>Information on Statistical Illnesses: Statistics on Diseases</article-title><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hira.or.kr/ra/stcIlnsInfm/stcIlnsInfmView.do?pgmid=HIRAA030502000000&amp;sortSno=192&amp;utm_source=chatgpt.com" ext-link-type="uri">https://www.hira.or.kr/ra/stcIlnsInfm/stcIlnsInfmView.do?pgmid=HIRAA030502000000&amp;sortSno=192&amp;utm_source=chatgpt.com</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-21">(accessed on 21 March 2025)</date-in-citation></element-citation></ref><ref id="B19-ijms-26-08660"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name></person-group><article-title>Polyhexamethylene Guanidine Phosphate Enhanced Procoagulant Activity through Oxidative-Stress-Mediated Phosphatidylserine Exposure in Platelets</article-title><source>Toxics</source><year>2024</year><volume>12</volume><elocation-id>50</elocation-id><pub-id pub-id-type="doi">10.3390/toxics12010050</pub-id><pub-id pub-id-type="pmid">38251006</pub-id><pub-id pub-id-type="pmcid">PMC10820372</pub-id></element-citation></ref><ref id="B20-ijms-26-08660"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilbert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>L.E.</given-names></name></person-group><article-title>Cationic Antiseptics: Diversity of Action under a Common Epithet</article-title><source>J. Appl. Microbiol.</source><year>2005</year><volume>99</volume><fpage>703</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2005.02664.x</pub-id><pub-id pub-id-type="pmid">16162221</pub-id></element-citation></ref><ref id="B21-ijms-26-08660"><label>21.</label><element-citation publication-type="webpage"><article-title>The Special Investigation Commission on Humidifier Disinfectant Disaster and Sewol Ferry Disaster</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://socialdisasterscommission.co.kr/" ext-link-type="uri">https://socialdisasterscommission.co.kr/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-21">(accessed on 21 March 2025)</date-in-citation></element-citation></ref><ref id="B22-ijms-26-08660"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>K.H.</given-names></name></person-group><article-title>Polyhexamethylene Guanidine Phosphate-Induced ROS-Mediated DNA Damage Caused Cell Cycle Arrest and Apoptosis in Lung Epithelial Cells</article-title><source>J. Toxicol. Sci.</source><year>2019</year><volume>44</volume><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.2131/jts.44.415</pub-id><pub-id pub-id-type="pmid">31168028</pub-id></element-citation></ref><ref id="B23-ijms-26-08660"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Song</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Tae</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Integration of Transcriptomics, Proteomics and Metabolomics Identifies Biomarkers for Pulmonary Injury by Polyhexamethylene Guanidine Phosphate (PHMG-P-p), a Humidifier Disinfectant, in Rats</article-title><source>Arch. Toxicol.</source><year>2020</year><volume>94</volume><fpage>887</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1007/s00204-020-02657-x</pub-id><pub-id pub-id-type="pmid">32080758</pub-id></element-citation></ref><ref id="B24-ijms-26-08660"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.R.</given-names></name></person-group><article-title>Polyhexamethylene Guanidine Phosphate Induces Apoptosis through Endoplasmic Reticulum Stress in Lung Epithelial Cells</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>1215</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22031215</pub-id><pub-id pub-id-type="pmid">33530568</pub-id><pub-id pub-id-type="pmcid">PMC7865558</pub-id></element-citation></ref><ref id="B25-ijms-26-08660"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Longitudinal Long Term Follow-Up Investigation on the Carcinogenic Impact of Polyhexamethylene Guanidine Phosphate in Rat Models</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>7178</elocation-id><pub-id pub-id-type="pmid">38531959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-57605-x</pub-id><pub-id pub-id-type="pmcid">PMC10965910</pub-id></element-citation></ref><ref id="B26-ijms-26-08660"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Juang</surname><given-names>U.</given-names></name><name name-style="western"><surname>Gwon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name></person-group><article-title>Effect of CTMP1 Gene on Pulmonary Fibrosis</article-title><source>Toxicol. Res.</source><year>2025</year><volume>41</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">40291111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s43188-024-00269-6</pub-id><pub-id pub-id-type="pmcid">PMC12021751</pub-id></element-citation></ref><ref id="B27-ijms-26-08660"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.J.</given-names></name></person-group><article-title>Polyhexamethylene Guanidine Phosphate-Induced Necrosis May Be Linked to Pulmonary Fibrosis</article-title><source>Toxicol. Lett.</source><year>2022</year><volume>362</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2022.03.009</pub-id><pub-id pub-id-type="pmid">35430302</pub-id></element-citation></ref><ref id="B28-ijms-26-08660"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.Y.</given-names></name><etal/></person-group><article-title>Hematotoxic Effect of Respiratory Exposure to PHMG-P-p and Its Integrated Genetic Analysis</article-title><source>Toxics</source><year>2022</year><volume>10</volume><fpage>694</fpage><pub-id pub-id-type="pmid">36422902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/toxics10110694</pub-id><pub-id pub-id-type="pmcid">PMC9693004</pub-id></element-citation></ref><ref id="B29-ijms-26-08660"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.T.M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ea</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kam</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>J.P.</given-names></name></person-group><article-title>Randomized Trial of Desktop Humidifier for Dry Eye Relief in Computer Users</article-title><source>Optom. Vis. Sci.</source><year>2017</year><volume>94</volume><fpage>1052</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1097/OPX.0000000000001136</pub-id><pub-id pub-id-type="pmid">29035923</pub-id></element-citation></ref><ref id="B30-ijms-26-08660"><label>30.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>HIRA (Health Insurance Review and Assessment Service)</collab></person-group><article-title>Dry Eye Syndrome&#8217; Cannot Be Relieved even in Spring and Summer</article-title><year>2014</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020041000100&amp;brdScnBltNo=4&amp;brdBltNo=8709&amp;pageIndex=1" ext-link-type="uri">https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020041000100&amp;brdScnBltNo=4&amp;brdBltNo=8709&amp;pageIndex=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-21">(accessed on 21 March 2025)</date-in-citation></element-citation></ref><ref id="B31-ijms-26-08660"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.B.</given-names></name></person-group><article-title>Metabolomics profiling of valproic acid-induced symptoms resembling autism spectrum disorders using 1H NMR spectral analysis in rat model</article-title><source>J. Toxicol. Environ. Health A</source><year>2022</year><volume>85</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">34445937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15287394.2021.1967821</pub-id></element-citation></ref><ref id="B32-ijms-26-08660"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Integration of serum metabolomics and network pharmacology reveals the immunoenhancing mechanisms of Qishenbuqi capsules</article-title><source>Toxicol. Res.</source><year>2023</year><volume>12</volume><fpage>201</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1093/toxres/tfad008</pub-id><pub-id pub-id-type="pmcid">PMC10141780</pub-id><pub-id pub-id-type="pmid">37125330</pub-id></element-citation></ref><ref id="B33-ijms-26-08660"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Sulaiti</surname><given-names>H.</given-names></name><name name-style="western"><surname>Almaliti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Naman</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Al Thani</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name></person-group><article-title>Metabolomics approaches for the diagnosis, treatment, and better disease management of viral infections</article-title><source>Metabolites</source><year>2023</year><volume>13</volume><elocation-id>948</elocation-id><pub-id pub-id-type="doi">10.3390/metabo13080948</pub-id><pub-id pub-id-type="pmid">37623891</pub-id><pub-id pub-id-type="pmcid">PMC10456346</pub-id></element-citation></ref><ref id="B34-ijms-26-08660"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vo</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Trinh</surname><given-names>K.T.L.</given-names></name></person-group><article-title>Emerging biomarkers in metabolomics: Advancements in precision health and disease diagnosis</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>13190</elocation-id><pub-id pub-id-type="doi">10.3390/ijms252313190</pub-id><pub-id pub-id-type="pmid">39684900</pub-id><pub-id pub-id-type="pmcid">PMC11642057</pub-id></element-citation></ref><ref id="B35-ijms-26-08660"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Metabolomics-driven approaches for identifying therapeutic targets in drug discovery</article-title><source>MedComm (2020)</source><year>2024</year><volume>5</volume><fpage>e792</fpage><pub-id pub-id-type="doi">10.1002/mco2.792</pub-id><pub-id pub-id-type="pmid">39534557</pub-id><pub-id pub-id-type="pmcid">PMC11555024</pub-id></element-citation></ref><ref id="B36-ijms-26-08660"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghanem</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Kadry</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Abdel-Megeed</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Abdel-Hamid</surname><given-names>A.Z.</given-names></name></person-group><article-title>Metabolomics applications in disease diagnosis, treatment, and drug discovery</article-title><source>Egypt. Pharm. J.</source><year>2019</year><volume>18</volume><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.4103/epj.epj_10_19</pub-id></element-citation></ref><ref id="B37-ijms-26-08660"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizo-Roca</surname><given-names>D.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Zierath</surname><given-names>J.R.</given-names></name></person-group><article-title>Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes</article-title><source>J. Intern. Med.</source><year>2025</year><volume>297</volume><fpage>584</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1111/joim.20090</pub-id><pub-id pub-id-type="pmid">40289598</pub-id><pub-id pub-id-type="pmcid">PMC12087830</pub-id></element-citation></ref><ref id="B38-ijms-26-08660"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Covarrubias</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Mart&#237;nez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Del Bosque-Plata</surname><given-names>L.</given-names></name></person-group><article-title>The Potential of Metabolomics in Biomedical Applications</article-title><source>Metabolites</source><year>2022</year><volume>12</volume><elocation-id>194</elocation-id><pub-id pub-id-type="doi">10.3390/metabo12020194</pub-id><pub-id pub-id-type="pmid">35208267</pub-id><pub-id pub-id-type="pmcid">PMC8880031</pub-id></element-citation></ref><ref id="B39-ijms-26-08660"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asef</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Pickens</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Saavedra-Matiz</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Orsini</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Petritis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gaul</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>F.M.</given-names></name></person-group><article-title>Beyond targeted newborn screening: A nontargeted metabolomics workflow to investigate birthweight-metabolome correlations</article-title><source>Anal. Chem.</source><year>2025</year><volume>97</volume><fpage>6563</fpage><lpage>6570</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.4c06061</pub-id><pub-id pub-id-type="pmid">40100766</pub-id><pub-id pub-id-type="pmcid">PMC11966594</pub-id></element-citation></ref><ref id="B40-ijms-26-08660"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Suleiman</surname><given-names>M.</given-names></name><name name-style="western"><surname>P&#233;rez-L&#243;pez</surname><given-names>A.</given-names></name></person-group><article-title>Metabolomics in the Diagnosis and Prognosis of COVID-19</article-title><source>Front. Genet.</source><year>2021</year><volume>12</volume><elocation-id>721556</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2021.721556</pub-id><pub-id pub-id-type="pmid">34367265</pub-id><pub-id pub-id-type="pmcid">PMC8343128</pub-id></element-citation></ref><ref id="B41-ijms-26-08660"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schellhorn</surname><given-names>H.E.</given-names></name></person-group><article-title>Metabolomics of infectious diseases in the era of personalized medicine</article-title><source>Front. Mol. Biosci.</source><year>2023</year><volume>10</volume><elocation-id>1120376</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2023.1120376</pub-id><pub-id pub-id-type="pmid">37275959</pub-id><pub-id pub-id-type="pmcid">PMC10233009</pub-id></element-citation></ref><ref id="B42-ijms-26-08660"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>A Set of Global Metabolomic Biomarker Candidates to Predict the Risk of Dry Eye Disease</article-title><source>Front. Cell Dev. Biol.</source><year>2020</year><volume>8</volume><elocation-id>344</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.00344</pub-id><pub-id pub-id-type="pmid">32582687</pub-id><pub-id pub-id-type="pmcid">PMC7295093</pub-id></element-citation></ref><ref id="B43-ijms-26-08660"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vehof</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hysi</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>C.J.</given-names></name></person-group><article-title>A Metabolome-Wide Study of Dry Eye Disease Reveals Serum Androgens as Biomarkers</article-title><source>Ophthalmology</source><year>2017</year><volume>124</volume><fpage>505</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2016.12.011</pub-id><pub-id pub-id-type="pmid">28139245</pub-id><pub-id pub-id-type="pmcid">PMC5375174</pub-id></element-citation></ref><ref id="B44-ijms-26-08660"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fineide</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Tashbayev</surname><given-names>B.</given-names></name><name name-style="western"><surname>Elgst&#248;en</surname><given-names>K.B.P.</given-names></name><name name-style="western"><surname>Sand&#229;s</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Rootwelt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hynne</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>R&#230;der</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vehof</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dartt</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Tear and Saliva Metabolomics in Evaporative Dry Eye Disease in Females</article-title><source>Metabolites</source><year>2023</year><volume>13</volume><elocation-id>1125</elocation-id><pub-id pub-id-type="doi">10.3390/metabo13111125</pub-id><pub-id pub-id-type="pmid">37999221</pub-id><pub-id pub-id-type="pmcid">PMC10673540</pub-id></element-citation></ref><ref id="B45-ijms-26-08660"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Goo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.B.</given-names></name></person-group><article-title>Metabolomics approach to biomarkers of dry eye disease using <sup>1</sup>H-NMR in rats</article-title><source>J. Toxicol. Environ. Health A</source><year>2021</year><volume>84</volume><fpage>313</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">33393448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15287394.2020.1867274</pub-id></element-citation></ref><ref id="B46-ijms-26-08660"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Goo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.B.</given-names></name></person-group><article-title>Mass Spectrometry (MS)-Based Metabolomics of Plasma and Urine in Dry Eye Disease (DED)-Induced Rat Model</article-title><source>J. Toxicol. Environ. Health A</source><year>2025</year><volume>88</volume><fpage>122</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1080/15287394.2024.2393770</pub-id><pub-id pub-id-type="pmid">39185961</pub-id></element-citation></ref><ref id="B47-ijms-26-08660"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jie</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Identification of glutamine as a potential therapeutic target in dry eye disease</article-title><source>Signal Transduct. Target. Ther.</source><year>2025</year><volume>10</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-02119-1</pub-id><pub-id pub-id-type="pmid">39837870</pub-id><pub-id pub-id-type="pmcid">PMC11751114</pub-id></element-citation></ref><ref id="B48-ijms-26-08660"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name></person-group><article-title>Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis</article-title><source>Curr. Protoc. Bioinform.</source><year>2016</year><volume>55</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.1002/cpbi.11</pub-id><pub-id pub-id-type="pmid">27603023</pub-id></element-citation></ref><ref id="B49-ijms-26-08660"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name></person-group><article-title>Fibrosis as a Result of Polyhexamethylene Guanide Exposure in Cultured Statens Seruminstitut Rabbit Cornea (SIRC) Cells</article-title><source>Environ. Anal. Health Toxicol.</source><year>2021</year><volume>36</volume><fpage>e2021009</fpage><pub-id pub-id-type="pmid">34130374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5620/eaht.2021009</pub-id><pub-id pub-id-type="pmcid">PMC8421752</pub-id></element-citation></ref><ref id="B50-ijms-26-08660"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name></person-group><article-title>Eye Irritation Tests of Polyhexamethylene Guanidine Phosphate (PHMG) and Chloromethylisothiazolinone/Methylisothiazolinone (CMIT/MIT) Using a Tissue Model of Reconstructed Human Cornea-Like Epithelium</article-title><source>Environ. Health Toxicol.</source><year>2019</year><volume>34</volume><fpage>e2019004</fpage><pub-id pub-id-type="pmid">31286748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5620/eht.e2019004</pub-id><pub-id pub-id-type="pmcid">PMC6620617</pub-id></element-citation></ref><ref id="B51-ijms-26-08660"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kirillova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Erimbetov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shatalov</surname><given-names>D.</given-names></name></person-group><article-title>Toxicity and Safety Analysis of Polyhexamethylene Guanidine: A Comprehensive Systematic Review</article-title><source>Sci. Pharm.</source><year>2024</year><volume>3</volume><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.58920/sciphar0303263</pub-id></element-citation></ref><ref id="B52-ijms-26-08660"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Paiva</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Corrales</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>V.Y.</given-names></name><name name-style="western"><surname>Farley</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Niederkorn</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.Q.</given-names></name><name name-style="western"><surname>Pflugfelder</surname><given-names>S.C.</given-names></name></person-group><article-title>Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2007</year><volume>48</volume><fpage>2553</fpage><lpage>2560</lpage><pub-id pub-id-type="pmid">17525184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.07-0069</pub-id></element-citation></ref><ref id="B53-ijms-26-08660"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.K.</given-names></name></person-group><article-title>Noninvasive Imaging of Conjunctival Goblet Cells as a Method for Diagnosing Dry Eye Disease in an Experimental Mouse Model</article-title><source>Transl. Vis. Sci. Technol.</source><year>2023</year><volume>12</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1167/tvst.12.12.22</pub-id><pub-id pub-id-type="pmcid">PMC10755591</pub-id><pub-id pub-id-type="pmid">38149964</pub-id></element-citation></ref><ref id="B54-ijms-26-08660"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Massingale</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Vallabhajosyula</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Asbell</surname><given-names>P.A.</given-names></name></person-group><article-title>Analysis of Inflammatory Cytokines in the Tears of Dry Eye Patients</article-title><source>Cornea</source><year>2009</year><volume>28</volume><fpage>1023</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1097/ico.0b013e3181a16578</pub-id><pub-id pub-id-type="pmid">19724208</pub-id></element-citation></ref><ref id="B55-ijms-26-08660"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corazza</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bacchi Reggiani</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taroni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giannaccare</surname><given-names>G.</given-names></name><name name-style="western"><surname>Versura</surname><given-names>P.</given-names></name></person-group><article-title>Dry Eye Disease and Tear Cytokine Levels&#8212;A Meta-Analysis</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>3111</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21093111</pub-id><pub-id pub-id-type="pmid">32354090</pub-id><pub-id pub-id-type="pmcid">PMC7246678</pub-id></element-citation></ref><ref id="B56-ijms-26-08660"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Urine Metabolomics Analysis for Biomarker Discovery and Detection of Jaundice Syndrome in Patients with Liver Disease</article-title><source>Mol. Cell Proteom.</source><year>2012</year><volume>11</volume><fpage>370</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1074/mcp.M111.016006</pub-id><pub-id pub-id-type="pmid">22505723</pub-id><pub-id pub-id-type="pmcid">PMC3412968</pub-id></element-citation></ref><ref id="B57-ijms-26-08660"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Abliz</surname><given-names>Z.</given-names></name></person-group><article-title>Global Metabolomics Reveals Potential Urinary Biomarkers of Esophageal Squamous Cell Carcinoma for Diagnosis and Staging</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>35010</elocation-id><pub-id pub-id-type="doi">10.1038/srep35010</pub-id><pub-id pub-id-type="pmid">27725730</pub-id><pub-id pub-id-type="pmcid">PMC5057114</pub-id></element-citation></ref><ref id="B58-ijms-26-08660"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anesi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rubert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oluwagbemigun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Orozco-Ruiz</surname><given-names>X.</given-names></name><name name-style="western"><surname>N&#246;thlings</surname><given-names>U.</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>M.M.B.</given-names></name><name name-style="western"><surname>Mattivi</surname><given-names>F.</given-names></name></person-group><article-title>Metabolic Profiling of Human Plasma and Urine, Targeting Tryptophan, Tyrosine and Branched Chain Amino Acid Pathways</article-title><source>Metabolites</source><year>2019</year><volume>9</volume><elocation-id>261</elocation-id><pub-id pub-id-type="doi">10.3390/metabo9110261</pub-id><pub-id pub-id-type="pmid">31683910</pub-id><pub-id pub-id-type="pmcid">PMC6918267</pub-id></element-citation></ref><ref id="B59-ijms-26-08660"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aronov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zakharkin</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Perroud</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>R.H.</given-names></name></person-group><article-title>Urine Metabolomics Analysis for Kidney Cancer Detection and Biomarker Discovery</article-title><source>Mol. Cell Proteom.</source><year>2009</year><volume>8</volume><fpage>558</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1074/mcp.M800165-MCP200</pub-id><pub-id pub-id-type="pmcid">PMC2649817</pub-id><pub-id pub-id-type="pmid">19008263</pub-id></element-citation></ref><ref id="B60-ijms-26-08660"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tohge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fernie</surname><given-names>A.R.</given-names></name></person-group><article-title>Combining Genetic Diversity, Informatics and Metabolomics to Facilitate Annotation of Plant Gene Function</article-title><source>Nat. Protoc.</source><year>2010</year><volume>5</volume><fpage>1210</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1038/nprot.2010.82</pub-id><pub-id pub-id-type="pmid">20539294</pub-id></element-citation></ref><ref id="B61-ijms-26-08660"><label>61.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name></person-group><article-title>Metabolomics in humans and other mammals</article-title><source>Metabolome Analysis: An Introduction</source><person-group person-group-type="editor"><name name-style="western"><surname>Villas-Boas</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smedsgaard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>M.A.E.</given-names></name><name name-style="western"><surname>Roessner-Tunali</surname><given-names>U.</given-names></name></person-group><publisher-name>John Wiley and Sons</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2007</year><fpage>280</fpage><lpage>296</lpage></element-citation></ref><ref id="B62-ijms-26-08660"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruzat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Macedo Rogero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keane</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Curi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Newsholme</surname><given-names>P.</given-names></name></person-group><article-title>Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>1564</elocation-id><pub-id pub-id-type="doi">10.3390/nu10111564</pub-id><pub-id pub-id-type="pmid">30360490</pub-id><pub-id pub-id-type="pmcid">PMC6266414</pub-id></element-citation></ref><ref id="B63-ijms-26-08660"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haroon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Sanacora</surname><given-names>G.</given-names></name></person-group><article-title>Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><fpage>193</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/npp.2016.199</pub-id><pub-id pub-id-type="pmid">27629368</pub-id><pub-id pub-id-type="pmcid">PMC5143501</pub-id></element-citation></ref><ref id="B64-ijms-26-08660"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>The Role of Amino Acid Metabolism in Inflammatory Bowel Disease and Other Inflammatory Diseases</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1284133</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1284133</pub-id><pub-id pub-id-type="pmid">37936710</pub-id><pub-id pub-id-type="pmcid">PMC10626463</pub-id></element-citation></ref><ref id="B65-ijms-26-08660"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parfenova</surname><given-names>H.</given-names></name><name name-style="western"><surname>Basuroy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tcheranova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Regan</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Leffler</surname><given-names>C.W.</given-names></name></person-group><article-title>Glutamate Induces Oxidative Stress and Apoptosis in Cerebral Vascular Endothelial Cells: Contributions of HO-1 and HO-2 to Cytoprotection</article-title><source>Am. J. Physiol. Cell Physiol.</source><year>2006</year><volume>290</volume><fpage>C1399</fpage><lpage>C1410</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00386.2005</pub-id><pub-id pub-id-type="pmid">16371440</pub-id></element-citation></ref><ref id="B66-ijms-26-08660"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alarcon-Aguilar</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Almanza-Perez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blancas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Angeles</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garcia-Macedo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>M.</given-names></name></person-group><article-title>Glycine regulates the production of pro-inflammatory cytokines in lean and monosodium glutamate-obese mice</article-title><source>Eur. J. Pharmacol.</source><year>2008</year><volume>599</volume><fpage>152</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">18930730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2008.09.047</pub-id></element-citation></ref><ref id="B67-ijms-26-08660"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguayo-Cer&#243;n</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>S&#225;nchez-Mu&#241;oz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gutierrez-Rojas</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Acevedo-Villavicencio</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Flores-Zarate</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Giacoman-Martinez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Villafa&#241;a</surname><given-names>S.</given-names></name><name name-style="western"><surname>Romero-Nava</surname><given-names>R.</given-names></name></person-group><article-title>Glycine: The Smallest Anti-Inflammatory Micronutrient</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>11236</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241411236</pub-id><pub-id pub-id-type="pmid">37510995</pub-id><pub-id pub-id-type="pmcid">PMC10379184</pub-id></element-citation></ref><ref id="B68-ijms-26-08660"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tauffenberger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fiumelli</surname><given-names>H.</given-names></name><name name-style="western"><surname>Almustafa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Magistretti</surname><given-names>P.J.</given-names></name></person-group><article-title>Lactate and Pyruvate Promote Oxidative Stress Resistance Through Hormetic ROS Signaling</article-title><source>Cell Death Dis.</source><year>2019</year><volume>10</volume><fpage>653</fpage><pub-id pub-id-type="doi">10.1038/s41419-019-1877-6</pub-id><pub-id pub-id-type="pmid">31506428</pub-id><pub-id pub-id-type="pmcid">PMC6737085</pub-id></element-citation></ref><ref id="B69-ijms-26-08660"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Mallet</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.H.</given-names></name></person-group><article-title>Pyruvate Protects Mitochondria from Oxidative Stress in Human Neuroblastoma SK-N-SH Cells</article-title><source>Brain Res.</source><year>2007</year><volume>1132</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.11.032</pub-id><pub-id pub-id-type="pmid">17174285</pub-id><pub-id pub-id-type="pmcid">PMC1853247</pub-id></element-citation></ref><ref id="B70-ijms-26-08660"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Son</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name></person-group><article-title>Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses</article-title><source>Life</source><year>2021</year><volume>11</volume><elocation-id>69</elocation-id><pub-id pub-id-type="doi">10.3390/life11010069</pub-id><pub-id pub-id-type="pmid">33477822</pub-id><pub-id pub-id-type="pmcid">PMC7832849</pub-id></element-citation></ref><ref id="B71-ijms-26-08660"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>L.A.J.</given-names></name></person-group><article-title>A Role for the Krebs Cycle Intermediate Citrate in Metabolic Reprogramming in Innate Immunity and Inflammation</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>141</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00141</pub-id><pub-id pub-id-type="pmid">29459863</pub-id><pub-id pub-id-type="pmcid">PMC5807345</pub-id></element-citation></ref><ref id="B72-ijms-26-08660"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bazer</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rhoads</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Satterfield</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name></person-group><article-title>Arginine Metabolism and Nutrition in Growth, Health and Disease</article-title><source>Amino Acids</source><year>2009</year><volume>37</volume><fpage>153</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1007/s00726-008-0210-y</pub-id><pub-id pub-id-type="pmid">19030957</pub-id><pub-id pub-id-type="pmcid">PMC2677116</pub-id></element-citation></ref><ref id="B73-ijms-26-08660"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gemici Karaaslan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kiykim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burtecene</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gokden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cansever</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hopurcuoglu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cengiz</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Topcu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zubario&#287;lu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kiykim</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Amino Acid Metabolism and Immune Dysfunction in Urea Cycle Disorders: T and B Cell Perspectives</article-title><source>J. Inherit. Metab. Dis.</source><year>2025</year><volume>48</volume><fpage>e70009</fpage><pub-id pub-id-type="doi">10.1002/jimd.70009</pub-id><pub-id pub-id-type="pmid">39957310</pub-id><pub-id pub-id-type="pmcid">PMC11831096</pub-id></element-citation></ref><ref id="B74-ijms-26-08660"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zotta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zaslona</surname><given-names>Z.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>L.A.</given-names></name></person-group><article-title>Is Citrate a Critical Signal in Immunity and Inflammation?</article-title><source>J. Cell Signal.</source><year>2020</year><volume>1</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.33696/Signaling.1.017</pub-id></element-citation></ref><ref id="B75-ijms-26-08660"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Reyes</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group><article-title>Mitochondrial TCA Cycle Metabolites Control Physiology and Disease</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13668-3</pub-id><pub-id pub-id-type="pmid">31900386</pub-id><pub-id pub-id-type="pmcid">PMC6941980</pub-id></element-citation></ref><ref id="B76-ijms-26-08660"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Bohannon</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Sherwood</surname><given-names>E.R.</given-names></name></person-group><article-title>Regulation of Leukocyte Function by Citric Acid Cycle Intermediates</article-title><source>J. Leukoc. Biol.</source><year>2019</year><volume>106</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1002/JLB.3MIR1118-415R</pub-id><pub-id pub-id-type="pmid">30791134</pub-id><pub-id pub-id-type="pmcid">PMC6597293</pub-id></element-citation></ref><ref id="B77-ijms-26-08660"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Frezza</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prag</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Chouchani</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>E.L.</given-names></name></person-group><article-title>Coupling Krebs Cycle Metabolites to Signalling in Immunity and Cancer</article-title><source>Nat. Metab.</source><year>2019</year><volume>1</volume><fpage>16</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/s42255-018-0014-7</pub-id><pub-id pub-id-type="pmid">31032474</pub-id><pub-id pub-id-type="pmcid">PMC6485344</pub-id></element-citation></ref><ref id="B78-ijms-26-08660"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramendra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ayala</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tung</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Isnard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Routy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Nijnik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Langlais</surname><given-names>D.</given-names></name></person-group><article-title>Glutathione Metabolism Is a Regulator of the Acute Inflammatory Response of Monocytes to (1&#8594;3)-&#946;-D-Glucan</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>694152</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.694152</pub-id><pub-id pub-id-type="pmid">34858388</pub-id><pub-id pub-id-type="pmcid">PMC8631827</pub-id></element-citation></ref><ref id="B79-ijms-26-08660"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mak</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Grusdat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Dostert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nonnenmacher</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>M.</given-names></name><name name-style="western"><surname>Binsfeld</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Br&#252;stle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Itsumi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Glutathione Primes T Cell Metabolism for Inflammation</article-title><source>Immunity</source><year>2017</year><volume>46</volume><fpage>675</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.03.019</pub-id><pub-id pub-id-type="pmid">28423341</pub-id></element-citation></ref><ref id="B80-ijms-26-08660"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maire</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pasquis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gr&#233;goire</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fourgeux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Acar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bretillon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Creuzot-Garcher</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Joffre</surname><given-names>C.</given-names></name></person-group><article-title>Time Course of Ocular Surface and Lacrimal Gland Changes in a New Scopolamine-Induced Dry Eye Model</article-title><source>Graefes Arch. Clin. Exp. Ophthalmol.</source><year>2008</year><volume>246</volume><fpage>857</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1007/s00417-008-0784-9</pub-id><pub-id pub-id-type="pmid">18357464</pub-id></element-citation></ref><ref id="B81-ijms-26-08660"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maire</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pasquis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gr&#233;goire</surname><given-names>S.</given-names></name><name name-style="western"><surname>Acar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bron</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bretillon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Creuzot-Garcher</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Joffre</surname><given-names>C.</given-names></name></person-group><article-title>Efficacy of a 2-Month Dietary Supplementation with Polyunsaturated Fatty Acids in Dry Eye Induced by Scopolamine in a Rat Model</article-title><source>Graefes Arch. Clin. Exp. Ophthalmol.</source><year>2009</year><volume>247</volume><fpage>1039</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1007/s00417-009-1080-z</pub-id><pub-id pub-id-type="pmid">19415319</pub-id></element-citation></ref><ref id="B82-ijms-26-08660"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>K.C.</given-names></name></person-group><article-title>Effectiveness of Topical Infliximab in a Mouse Model of Experimental Dry Eye</article-title><source>Cornea</source><year>2012</year><volume>31</volume><issue>(Suppl. S1)</issue><fpage>S25</fpage><lpage>S31</lpage><pub-id pub-id-type="doi">10.1097/ICO.0b013e31826a80ea</pub-id><pub-id pub-id-type="pmid">23038030</pub-id></element-citation></ref><ref id="B83-ijms-26-08660"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>K.C.</given-names></name></person-group><article-title>Therapeutic Effect of Topical Adiponectin in a Mouse Model of Desiccating Stress-Induced Dry Eye</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2013</year><volume>54</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-10648</pub-id><pub-id pub-id-type="pmid">23211823</pub-id></element-citation></ref><ref id="B84-ijms-26-08660"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.H.</given-names></name></person-group><article-title>Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2011</year><volume>52</volume><fpage>7267</fpage><lpage>7273</lpage><pub-id pub-id-type="doi">10.1167/iovs.11-7231</pub-id><pub-id pub-id-type="pmid">21849424</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-26-08660-f001" orientation="portrait"><label>Figure 1</label><caption><p>Images of the eyes of rat in the control groups, DED induced group, positive control group and PHMG-p treated groups were photographed with a microscope after 13 day desiccation stress and after the instillation of scopolamine eye drops. (<bold>A</bold>) Corneal fluorescein staining. (<bold>B</bold>) Corneal damage. (<bold>C</bold>) Tear volume. (<bold>D</bold>) Tear break-up time (TBUT). * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001 compared with the control group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g001.jpg"/></fig><fig position="float" id="ijms-26-08660-f002" orientation="portrait"><label>Figure 2</label><caption><p>Effect of control groups, DED induced group, positive control group and PHMG-p treated groups on detached conjunctive goblet cell of the rats. (<bold>A</bold>) Quantitative analysis of conjunctive goblet cell density (cells/mm<sup>2</sup>) in each group. (<bold>B</bold>) Representative histological image of conjunctive goblet cell. The result of each group are shown as mean &#177; SD. *** <italic toggle="yes">p</italic> &lt; 0.001 compared with the control group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g002.jpg"/></fig><fig position="float" id="ijms-26-08660-f003" orientation="portrait"><label>Figure 3</label><caption><p>The change of immune index markers in the cornea epithelium of the rats. (<bold>A</bold>) Quantitative analysis of IL-6, IL-1&#946;, and TNF-&#945; expression in the cornea epithelium. (<bold>B</bold>) Representative immunohistochemical images. Values are shown as mean &#177; SD. ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001 compared with the control group. Red arrows indicate cytokine expression.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g003.jpg"/></fig><fig position="float" id="ijms-26-08660-f004" orientation="portrait"><label>Figure 4</label><caption><p>In global profiling, principal component analysis (PCA) (R<sup>2</sup>X = 0.749, Q<sup>2</sup> = 0.666) models (<bold>A</bold>) and orthogonal projections to latent structures-discriminant analysis (OPLS-DA) (R<sup>2</sup>X = 0.738, R<sup>2</sup>Y = 0.181, Q<sup>2</sup> = 0.0871) models (<bold>B</bold>) results after NMR analysis of control, DED group and PHMG-p treated groups in plasma samples. Global profiling of PCA (R<sup>2</sup>X = 0.883, Q<sup>2</sup> = 0.825) (<bold>C</bold>) and OPLS-DA (R<sup>2</sup>X = 0.882, R<sup>2</sup>Y = 0.174, Q<sup>2</sup> = 0.0955) (<bold>D</bold>) using NMR data from urine samples. &#9650;, Control; <named-content content-type="color:#EE0000">&#9650;</named-content>, DED group; <named-content content-type="color:blue">&#9650;</named-content>, DED + BAC; <named-content content-type="color:#7030A0">&#9650;</named-content>, DED + PHMG-p 0.1%; <named-content content-type="color:#00CC00">&#9650;</named-content>, DED + PHMG-p 0.3%; <named-content content-type="color:yellow">&#9650;</named-content>, PHMG-p 0.1%; <named-content content-type="color:#FFC000">&#9650;</named-content>, PHMG-p 0.3%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g004.jpg"/></fig><fig position="float" id="ijms-26-08660-f005" orientation="portrait"><label>Figure 5</label><caption><p>In target profiling, principal component analysis (PCA) (R<sup>2</sup>X = 0.947, Q<sup>2</sup> = 0.816) models (<bold>A</bold>) and orthogonal projections to latent structures-discriminant analysis (OPLS-DA) (R<sup>2</sup>X = 0.991, R<sup>2</sup>Y = 0.585, Q<sup>2</sup> = 0.109) models (<bold>B</bold>) results after NMR analysis of control and DED group in plasma sample. Variable importance plot (VIP) (<bold>C</bold>) shows the major urine metabolites that contributed to separate the clusters. Metabolites set enrichment overview in plasma samples (<bold>D</bold>). &#9650;, Control; <named-content content-type="color:#EE0000">&#9650;</named-content>, DED group; <named-content content-type="color:blue">&#9650;</named-content>, DED + BAC; <named-content content-type="color:#7030A0">&#9650;</named-content>, DED + PHMG-p 0.1%; <named-content content-type="color:#00CC00">&#9650;</named-content>, DED + PHMG-p 0.3%; <named-content content-type="color:yellow">&#9650;</named-content>, PHMG-p 0.1%; <named-content content-type="color:#FFC000">&#9650;</named-content>, PHMG-p 0.3%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g005.jpg"/></fig><fig position="float" id="ijms-26-08660-f006" orientation="portrait"><label>Figure 6</label><caption><p>Concentrations of endogenous metabolites in plasma samples for DED induced and PHMG-p treatment to rats. ANOVA test was performed to assess statistical significance compared with control and treatment. Error bars are expressed as S.D. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g006.jpg"/></fig><fig position="float" id="ijms-26-08660-f007" orientation="portrait"><label>Figure 7</label><caption><p>Expected plasma metabolic pathway network of metabolites related to PHMG-p exposure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g007.jpg"/></fig><fig position="float" id="ijms-26-08660-f008" orientation="portrait"><label>Figure 8</label><caption><p>Principal component analysis (PCA) (R<sup>2</sup>X = 0.463, Q<sup>2</sup> = 0.0756) (<bold>A</bold>) model and orthogonal projections to latent structures-discriminant analysis (OPLS-DA) (R<sup>2</sup>X = 0.832, R<sup>2</sup>Y = 0.586, Q<sup>2</sup> = 0.31) (<bold>B</bold>) in target profiling of urine samples. Variable importance plot (VIP) (<bold>C</bold>) shows the major urine metabolites that contributed to separate the clusters. Metabolites set enrichment overview in urine samples (<bold>D</bold>). &#9650;, Control; <named-content content-type="color:#EE0000">&#9650;</named-content>, DED group; <named-content content-type="color:blue">&#9650;</named-content>, DED+BAC; <named-content content-type="color:#7030A0">&#9650;</named-content>, DED+PHMG-p 0.1%; <named-content content-type="color:#00CC00">&#9650;</named-content>, DED+PHMG-p 0.3%; <named-content content-type="color:yellow">&#9650;</named-content>, PHMG-p 0.1%; <named-content content-type="color:#FFC000">&#9650;</named-content>, PHMG-p 0.3%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g008.jpg"/></fig><fig position="float" id="ijms-26-08660-f009" orientation="portrait"><label>Figure 9</label><caption><p>Concentrations of endogenous metabolites in urine samples for DED induced and PHMG-p treatment to rats. ANOVA test was performed to assess statistical significance compared with control and treatment. Error bars are expressed as S.D. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g009.jpg"/></fig><fig position="float" id="ijms-26-08660-f010" orientation="portrait"><label>Figure 10</label><caption><p>Expected urinary metabolic pathway network of metabolites related to PHMG-p exposure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08660-g010.jpg"/></fig><table-wrap position="float" id="ijms-26-08660-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08660-t001_Table 1</object-id><label>Table 1</label><caption><p>Expected pathway based on high-VIP-scored (VIP &gt; 0.5) metabolites in rat plasma using MetaboAnalyst (6.0).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="8" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Plasma</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathway</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expected</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hits</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;log(<italic toggle="yes">p</italic>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Holm Adjust</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDR</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glycine and Serine Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">59</td><td align="center" valign="middle" rowspan="1" colspan="1">1.06</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.48 &#215; 10<sup>&#8722;6</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.000243</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000243</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000243</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glucose-Alanine Cycle</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.234</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4.73 &#215; 10<sup>&#8722;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.00454</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00155</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00155</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Urea Cycle</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">0.503</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">7.85 &#215; 10<sup>&#8722;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.00746</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00192</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00192</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glutamate Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">0.862</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000106</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00994</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00207</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00207</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ammonia Recycling</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.557</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000131</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0122</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00211</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00211</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alanine Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.305</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000151</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0139</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00211</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00211</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Arginine and Proline Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">52</td><td align="center" valign="middle" rowspan="1" colspan="1">0.934</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00159</td><td align="center" valign="middle" rowspan="1" colspan="1">0.145</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0195</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0195</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Valine, Leucine and Isoleucine Degradation</td><td align="center" valign="middle" rowspan="1" colspan="1">59</td><td align="center" valign="middle" rowspan="1" colspan="1">1.06</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00283</td><td align="center" valign="middle" rowspan="1" colspan="1">0.255</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0308</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0308</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glutathione Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.359</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00459</td><td align="center" valign="middle" rowspan="1" colspan="1">0.409</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Transfer of Acetyl Groups into Mitochondria</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.395</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00606</td><td align="center" valign="middle" rowspan="1" colspan="1">0.533</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Citric Acid Cycle</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">0.575</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0174</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.133</td><td align="center" valign="middle" rowspan="1" colspan="1">0.133</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Amino Sugar Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.593</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.133</td><td align="center" valign="middle" rowspan="1" colspan="1">0.133</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gluconeogenesis</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.593</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.133</td><td align="center" valign="middle" rowspan="1" colspan="1">0.133</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ketone Body Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.234</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0212</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.136</td><td align="center" valign="middle" rowspan="1" colspan="1">0.136</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aspartate Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.629</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0222</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.136</td><td align="center" valign="middle" rowspan="1" colspan="1">0.136</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Carnitine Synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.395</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0569</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.328</td><td align="center" valign="middle" rowspan="1" colspan="1">0.328</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glycolysis</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">0.413</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0617</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.336</td><td align="center" valign="middle" rowspan="1" colspan="1">0.336</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cysteine Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">0.467</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0768</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.396</td><td align="center" valign="middle" rowspan="1" colspan="1">0.396</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Selenoamino Acid Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.485</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0821</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.402</td><td align="center" valign="middle" rowspan="1" colspan="1">0.402</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nicotinate and Nicotinamide Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.629</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.128</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.544</td><td align="center" valign="middle" rowspan="1" colspan="1">0.544</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acid Biosynthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.629</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.476</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.992</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.992</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-26-08660-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08660-t002_Table 2</object-id><label>Table 2</label><caption><p>Expected pathway based on high-VIP-scored (VIP &gt; 0.5) metabolites in rat urine using MetaboAnalyst (6.0).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="8" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Urine</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathway</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expected</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hits</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;log(<italic toggle="yes">p</italic>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Holm Adjust</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDR</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ketone Body Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.272</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00199</td><td align="center" valign="middle" rowspan="1" colspan="1">0.193</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0973</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0973</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Citric Acid Cycle</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">0.671</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00351</td><td align="center" valign="middle" rowspan="1" colspan="1">0.337</td><td align="center" valign="middle" rowspan="1" colspan="1">0.115</td><td align="center" valign="middle" rowspan="1" colspan="1">0.115</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Carnitine Synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.461</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00946</td><td align="center" valign="middle" rowspan="1" colspan="1">0.899</td><td align="center" valign="middle" rowspan="1" colspan="1">0.232</td><td align="center" valign="middle" rowspan="1" colspan="1">0.232</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glutamate Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0152</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.298</td><td align="center" valign="middle" rowspan="1" colspan="1">0.298</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ammonia Recycling</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0245</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.354</td><td align="center" valign="middle" rowspan="1" colspan="1">0.354</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glucose-Alanine Cycle</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.272</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0284</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.354</td><td align="center" valign="middle" rowspan="1" colspan="1">0.354</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gluconeogenesis</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.692</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0289</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.354</td><td align="center" valign="middle" rowspan="1" colspan="1">0.354</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aspartate Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.734</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0337</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.367</td><td align="center" valign="middle" rowspan="1" colspan="1">0.367</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alanine Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.356</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0471</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.462</td><td align="center" valign="middle" rowspan="1" colspan="1">0.462</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ethanol Degradation</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.398</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0577</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.514</td><td align="center" valign="middle" rowspan="1" colspan="1">0.514</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Transfer of Acetyl Groups into Mitochondria</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.461</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0751</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.614</td><td align="center" valign="middle" rowspan="1" colspan="1">0.614</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Arginine and Proline Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">52</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0906</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Oxidation of Branched Chain Fatty Acids</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">0.545</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.101</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Phytanic Acid Peroxisomal Oxidation</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">0.545</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.101</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Phenylalanine and Tyrosine Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.566</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.107</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Urea Cycle</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">0.587</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.114</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glycine and Serine Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">59</td><td align="center" valign="middle" rowspan="1" colspan="1">1.24</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.121</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tryptophan Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">59</td><td align="center" valign="middle" rowspan="1" colspan="1">1.24</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.121</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Amino Sugar Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.692</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Beta-Alanine Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">0.713</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.157</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nicotinate and Nicotinamide Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.734</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.165</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fatty Acid Biosynthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.734</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.165</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Phenylacetate Metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.189</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.174</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lactose Degradation</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.189</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.174</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td><td align="center" valign="middle" rowspan="1" colspan="1">0.683</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Malate-Aspartate Shuttle</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.192</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.722</td><td align="center" valign="middle" rowspan="1" colspan="1">0.722</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taurine and Hypotaurine Metabolism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.762</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.762</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>